var title_f14_58_15264="Spinal cord myxopap epend MRI";
var content_f14_58_15264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal cord myxopapillary ependymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal and axial contrast enhanced MRI study of a small, cauda equine lesion (arrow) found in a 49-year-old woman with left buttock and leg pain. Complete resection was performed and the diagnosis of myxopapillary ependymoma was confirmed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Welch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15264=[""].join("\n");
var outline_f14_58_15264=null;
var title_f14_58_15265="Amoxicillin and cloxacillin: International drug information";
var content_f14_58_15265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amoxicillin and cloxacillin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2222583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Cloxacillin and Amoxicillin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2222584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2222585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of otitis media, sinusitis, and infections caused by susceptible organisms involving the lower respiratory tract, skin, skin structure, and genitourinary tract (spectrum same as amoxicillin with additional coverage of beta-lactamase producing",
"     <i>",
"      B. catarrhalis",
"     </i>",
"     ),",
"     <i>",
"      H. influenzae, E. coli,",
"     </i>",
"     and",
"     <i>",
"      Klebsiella",
"     </i>",
"     sp. caused by penicillinase producing",
"     <i>",
"      S. aureus",
"     </i>",
"     or",
"     <i>",
"      S. epidermidis",
"     </i>",
"     . Infections of the skin, soft tissue, respiratory tract, ear, nose, throat, genitourinary tract, bone, intestine, surgical site, and infective endocarditis.",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2223597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage expressed as combined amount of amoxicillin plus cloxacillin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 2-12 years: 250-500 mg 3 times/day, preferably 1 hour prior to  meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 500-1000 mg 3 times/day, preferably 1 hour prior to meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2223598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 250 mg: amoxicillin 125 mg and cloxacillin sodium 125 mg; 500 mg: amoxicillin 250 mg and cloxacillin sodium 250 mg; 1 g: amoxicillin 500 mg and cloxacillin sodium 500 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10508 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15265=[""].join("\n");
var outline_f14_58_15265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2222583\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2222584\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2222585\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2223597\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821210\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2223598\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_58_15266="Asthma self assess PI";
var content_f14_58_15266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Self-assessment form*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 770px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These questions are examples and do not represent a standardized assessment instrument. Other examples of asthma control questions: Asthma Control Questionnaire (Juniper); Asthma Therapy Assessment Questionnaire (Vollmer); Asthma Control Test (Nathan); Asthma Control Score (Boulet).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood,and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15266=[""].join("\n");
var outline_f14_58_15266=null;
var title_f14_58_15267="Concealed His extrasystole";
var content_f14_58_15267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Concealed His extrasystoles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient was asymptomatic with high-grade AV block on surface tracings. All 12 surface leads are shown. Representative intracardiac tracings are the distal His bundle electrogram (HIS d) and the proximal His bundle electrogram (HIS p). Baseline recordings show infra-Hisian block (red arrows) with a significantly prolonged H-V interval. Concealed His extrasystoles can be seen (black arrows) which do not conduct to the ventricles and retrogradely penetrate the AV node and cause the next atrial impulse to block. A pacemaker was implanted in this patient not for His extrasystoles, but for concomitant severe His-Purkinje disease.",
"    <div class=\"footnotes\">",
"     A: atrial depolarization; AV: atrioventricular; H: His bundle depolarization; V: ventricular depolarization.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph J Germano, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15267=[""].join("\n");
var outline_f14_58_15267=null;
var title_f14_58_15268="Caudal regression syndrome";
var content_f14_58_15268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Caudal regression syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 490px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Infant of a diabetic mother with caudal regression syndrome. Top panel shows decreased growth of the left leg. In the bottom panel, a plain radiograph reveals absence of the sacrum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Cabrera-Mesa, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15268=[""].join("\n");
var outline_f14_58_15268=null;
var title_f14_58_15269="Naratriptan: Patient drug information";
var content_f14_58_15269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Naratriptan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=see_link\">",
"     see \"Naratriptan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amerge&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amerge&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Naratriptan;",
"     </li>",
"     <li>",
"      Teva-Naratriptan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to naratriptan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703476",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Chest pain or pressure, heart disease, pain in your legs while walking, poor bowel blood flow, very bad kidney disease, very bad liver disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703749",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a recent heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug to stop you from getting migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703843",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken almotriptan, eletriptan, frovatriptan, rizatriptan, sumatriptan, or zolmitriptan in the last 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken ergotamine, methysergide, or dihydroergotamine in the last 24 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4036462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you take this drug 10 or more days in a month your headaches may become worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache or if headache is not better after the first dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with liquids as early as you can after the attack has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695209",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your headache comes back after the first dose, 1 more dose may be taken 4 hours after the first one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10893 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F93BED5DA7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15269=[""].join("\n");
var outline_f14_58_15269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199952\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199953\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021023\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021025\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021024\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021029\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021030\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021032\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021027\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021033\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021034\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/9/6293?source=related_link\">",
"      Naratriptan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_58_15270="Second primary malignancies in patients with head and neck cancers";
var content_f14_58_15270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second primary malignancies in patients with head and neck cancers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15270/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15270/contributors\">",
"     Sandeep Samant, MD, FRCS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15270/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15270/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15270/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15270/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15270/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15270/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/58/15270/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with head and neck squamous cell carcinoma are at increased risk for the development of second primary malignancies compared with the general population. Such second primary cancers may be difficult to distinguish from locoregional recurrences. These second primary malignancies typically develop in the aerodigestive tract and contribute significantly to the shortened survival of patients treated for head and neck cancer.",
"   </p>",
"   <p>",
"    The epidemiology, diagnosis, and treatment of second primary malignancies will be reviewed here. Surveillance following the treatment of an initial head and neck cancer primary cancer for both second primary malignancy and for recurrent disease and the management of head and neck disease in patients who have already been treated for once head and neck cancer are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345501674\">",
"    <span class=\"h2\">",
"     Second primary vs locoregional recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for classifying a tumor as a second primary malignancy have remained consistent since they were first proposed in 1932 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histologic confirmation of malignancy in both the index and secondary tumors.",
"     </li>",
"     <li>",
"      There should be at least 2 cm of normal mucosa between the tumors. If the tumors are in the same location, then they should be separated in time by at least five years.",
"     </li>",
"     <li>",
"      Metastatic tumor should be excluded. As an example, a secondary lesion in the lung should be solitary and histologically different from the primary head and neck tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345501689\">",
"    <span class=\"h2\">",
"     Time to occurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second primary malignancies can be described according to their temporal relationship to the index tumor. Metachronous second primary tumors are diagnosed more than six months after the index tumor, while synchronous second primary cancers are identified within six months of the index tumor.",
"   </p>",
"   <p>",
"    Second primary malignancies are considered \"simultaneous\" when the cancer is diagnosed at the same time as the index tumor or during its initial diagnostic work-up. Simultaneous second primary tumors are often considered a subset of synchronous tumors. When two tumors are diagnosed simultaneously, the tumor diagnosed first is usually designated the index tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Simultaneous tumors require a carefully coordinated treatment strategy since the survival rate is poor. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H345501696\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of a second primary malignancy in patients who have had a squamous cell carcinoma of the head and neck is significantly increased compared with the age-matched general population. Furthermore, this increased risk is largely restricted to cancers of the aerodigestive tract and remains relatively constant over time after the initial diagnosis.",
"   </p>",
"   <p>",
"    Two large contemporary cancer registry studies provide insights into the magnitude and details of the increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 13 cancer registries in Europe, Asia, Australia, and Canada provides data on over 99,000 patients and approximately 490,000 person-years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/4\">",
"       4",
"      </a>",
"      ]. In this combined database, 10,826 second primaries were identified:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The 20-year cumulative risk of a second cancer was 36 percent and the standardized incidence ratio (SIR) for compared to the general population was 1.86.",
"     </li>",
"     <li>",
"      The most frequent second malignancy was lung cancer (20-year cumulative risk 13 percent, SIR 3.3).",
"     </li>",
"     <li>",
"      The highest relative increase in risk was for a second head and neck cancer (SIR 11.2).",
"     </li>",
"     <li>",
"      The increased risk of a second primary malignancy decreased with increasing age at the diagnosis of the first cancer. As an example, for patients with a second primary head and neck cancer, the SIR decreased progressively from 14.9 for those less than 56 years of age at the initial diagnosis to 8.4 for those 75 years of age or older. A similar progressive decrease in risk was observed for patients whose second primary was in the lung. Whether this reflected higher background rates of cancer with increasing age in the general population or the effect of other unidentified factors (tobacco, alcohol, genetics) is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A second study analyzed the frequency of second malignancies in 75,087 patients identified between 1975 and 2006 from the Surveillance, Epidemiology and End Results (SEER) database [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The SIR for a second primary solid tumor was 2.2. This corresponded to an excess absolute risk (EAR) of 168 cancers per 10,000 patient-years at risk (PYR).",
"     </li>",
"     <li>",
"      The biggest relative increase in risk was for a second primary cancer of the head and neck (SIR 12.4), and this contributed an EAR of 60 per 10,000 PYR.",
"     </li>",
"     <li>",
"      The incidence of lung cancer was also significantly increased (SIR 3.8). Because of the high frequency of lung cancer, this was the biggest contributor to the absolute increase in cancer incidence (EAR 75.2 per 10,000 PYR).",
"     </li>",
"     <li>",
"      Esophageal cancer was also markedly increased in incidence and was a significant contributor to the overall increase in cancer frequency in patients who originally presented with head and neck cancer (SIR 14.2 and EAR 14.2 per 10,000 PYR).",
"     </li>",
"     <li>",
"      There was only a minimal increase in the risk of solid tumors other than those of the head and neck, lung, and esophagus (SIR 1.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The site of the index cancer influences the most likely site of a second primary malignancy. As an example, in a series of 1257 patients with squamous cell carcinoma of the head and neck, patients with an index malignancy arising in the larynx were more like to develop a second primary cancer in the lung, while those arising in the oral cavity were more likely to develop a second primary in the head and neck or esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/6\">",
"     6",
"    </a>",
"    ]. This relationship has been observed in other studies as well [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with oropharyngeal cancer that is caused by human papillomavirus (HPV), there appears to be a decreased incidence of cancers of the upper aerodigestive tract compared with oropharyngeal cancer not associated with HPV [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, there is a statistically significant association with subsequent anogenital cancers, which are known to be associated with HPV (SIR 1.9), and there is also a statistically significant increase in oropharyngeal cancer in those who have had a prior HPV associated anogenital cancer (SIR 3.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasopharyngeal cancer is more frequent in Asian populations and is associated with Epstein Barr virus (EBV). The increase in second malignancies in that population is limited to the head and neck, and there is no significant increase in lung cancer or esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors influence the likelihood of developing one or more additional cancers, either in the head and neck or elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to tobacco and alcohol are well known risk factors for the development of head and neck cancer and are the primary factor associated with the increased frequency of second primary malignancies. These agents are thought to contribute to changes throughout the epithelium, and their continued use is associated with an increased risk of second malignancies. Smoking cessation appears to diminish the risk of a second primary malignancy after a diagnosis of head and neck cancer, although the magnitude of benefit is unclear. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link&amp;anchor=H3#H3\">",
"       \"Epidemiology and risk factors for head and neck cancer\", section on 'Risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple large studies have observed that the risk of a second primary malignancy is increased in patients with a head and neck cancer diagnosed at a relatively early age and this increased risk decreases with increasing age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/4,12\">",
"       4,12",
"      </a>",
"      ]. Whether this reflects higher background rates of cancer with increasing age in the general population or the effect of other unidentified factors (tobacco, alcohol, genetics) is unclear. (See",
"      <a class=\"local\" href=\"#H345501696\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of prior radiation therapy (RT) is complex. Previous treatment for head and neck cancer using external beam RT is associated with a decreased incidence of second primary cancers within the treatment fields. This observation has been attributed to treatment of premalignant epithelium and occult second primary tumors. In a Surveillance, Epidemiology and End Results (SEER) database study of 27,985 patients, the incidence of a second primary head and neck cancer was significantly decreased in those treated with RT compared with those whose primary cancer was managed with surgery (7.7 versus 10.5 percent at 15 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/13\">",
"       13",
"      </a>",
"      ]. However, exposure to RT may be associated with various cancers, such as thyroid cancer or sarcoma, in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/14\">",
"       14",
"      </a>",
"      ].Other factors associated with an increased risk of second primary malignancies may include poor oral hygiene, immunologic factors, and genetic factors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"       \"Epidemiology and risk factors for head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with a squamous cell carcinoma of the head and neck should include a detailed search for a potential simultaneous second primary malignancy of the upper aerodigestive tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular follow-up after treatment of an initial head and neck cancer is mandatory to identify a potential second primary malignancy and to look for evidence of recurrent disease from the index cancer. Although the risk of locoregional recurrence from the original tumor decreases over time, continued surveillance is needed because of the prolonged increased risk of a second primary tumor over time. (See",
"    <a class=\"local\" href=\"#H345501696\">",
"     'Incidence'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two key issues in the management of patients with squamous cell carcinoma of the head and neck are the prevention of development of a second primary malignancy and the treatment of a second primary, if a second primary does occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of chemoprevention of head and neck cancer is both to reduce recurrences from the index tumor and to prevent malignant conversion of premalignant lesions and the development of second primary malignancies. Cessation of smoking is particularly important in preventing the occurrence of second primary lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Numerous agents have been studied as potential chemopreventive agents. Unfortunately, none of these compounds have shown significant benefit in prospective, randomized studies and none of these have an established role in patients who have had squamous cell carcinoma of the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19017?source=see_link\">",
"     \"Chemoprevention in oral dysplasia and head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a second primary tumor develops in the head and neck region, options for treatment are limited by the scope and magnitude of the previous treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients whose initial management was surgical, either surgery or radiation therapy may be an option, depending upon the site and extent of the second primary tumor.",
"     </li>",
"     <li>",
"      For patients whose initial management consisted of radiation therapy, surgery is generally the treatment of choice in patients with a resectable tumor. However, surgery in a previously irradiated field is more complex and may increase the risks of poor wound healing acutely and severe fibrosis chronically.",
"      <br/>",
"      <br/>",
"      Reirradiation is a therapeutic option in carefully selected cases. When re-irradiation is used, standard doses are required for meaningful opportunity for local control. Factors that need to be considered include the previously treated volume and dose fractionation schedule, critical tissues and organs at risk, and time elapsed since the first treatment course. Local control is best with small, well-differentiated second primary tumors as opposed to recurrent disease. Reirradiation should only be considered if there are no other practical alternatives to treatment, since there is an increased risk of serious complications. To minimize the risk of serious complications, conformal therapy should be used [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"       \"Management of late complications of head and neck cancer and its treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issues and difficulties associated with the treatment of a second primary head and neck malignancy are similar to those for a patient with a recurrent disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link\">",
"     \"Treatment of locally recurrent head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link\">",
"     \"Reirradiation for locally recurrent head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"     \"Treatment of metastatic and recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of an individual patient is a function of the site and stage of the second primary, as well as comorbidities and the ability to treat the tumor in a definitive manner.",
"   </p>",
"   <p>",
"    General factors that can influence the prognosis following the diagnosis of a second primary malignancy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interval between the index cancer and the second primary: Patients with a metachronous second primary have a better prognosis than those who present with synchronous lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/3,12,17\">",
"       3,12,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Site of second primary: Patients with a second primary malignancy arising in the lung or in the esophagus have a worse prognosis than those with a second head and neck primary [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/18\">",
"       18",
"      </a>",
"      ]. Furthermore, patients with lung cancer after head and neck cancer have a worse prognosis than the general population of patients with lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15270/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of second primary malignancies in patients who have had an index squamous cell carcinoma of the head and neck is significantly increased compared with the general population. The risk of a second primary malignancy remains elevated for at least ten years and is restricted to tumors arising in the head and neck, lung, and esophagus. (See",
"      <a class=\"local\" href=\"#H345501696\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to tobacco and alcohol are the primary factors associated with the development of second primary malignancies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology and risk factors for head and neck cancer\", section on 'Smoking'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link&amp;anchor=H5#H5\">",
"       \"Epidemiology and risk factors for head and neck cancer\", section on 'Alcohol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The initial evaluation of a patient with a squamous carcinoma of the head and neck should include a detailed evaluation for the possible presence of a second primary malignancy. Prolonged posttreatment surveillance is also necessary for the early detection of second primary malignancies as well as recurrence of the index cancer. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"       \"Overview of the diagnosis and staging of head and neck cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"       \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients presenting with a second primary malignancy in the head and neck region present a therapeutic challenge due to the previous treatment received; treatment options are limited, and morbidity can be substantial. Nevertheless, selected patients with second primary malignancies may achieve long-term survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=see_link\">",
"       \"Treatment of locally recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1967057\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Sreekrishna Donepudi, who contributed to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/1\">",
"      Warren S, Gates O. Multiple primary malignant tumors. A survey of the literature and a statistical study. Am J Cancer 1932; 16:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/2\">",
"      Le&oacute;n X, Quer M, Diez S, et al. Second neoplasm in patients with head and neck cancer. Head Neck 1999; 21:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/3\">",
"      Di Martino E, Sellhaus B, Hausmann R, et al. Survival in second primary malignancies of patients with head and neck cancer. J Laryngol Otol 2002; 116:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/4\">",
"      Chuang SC, Scelo G, Tonita JM, et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer 2008; 123:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/5\">",
"      Morris LG, Sikora AG, Patel SG, et al. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011; 29:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/6\">",
"      Lin K, Patel SG, Chu PY, et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck 2005; 27:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/7\">",
"      Chen MC, Chen PT, Chan CH, et al. Second primary esophageal or lung cancer in patients with head and neck carcinoma in Taiwan: incidence and risk in relation to primary index tumor site. J Cancer Res Clin Oncol 2011; 137:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/8\">",
"      Chu PY, Chang SY, Huang JL, Tai SK. Different patterns of second primary malignancy in patients with squamous cell carcinoma of larynx and hypopharynx. Am J Otolaryngol 2010; 31:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/9\">",
"      Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24:5630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/10\">",
"      Huang SH, Perez-Ordonez B, Liu FF, et al. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/11\">",
"      Sikora AG, Morris LG, Sturgis EM. Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Arch Otolaryngol Head Neck Surg 2009; 135:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/12\">",
"      Rennemo E, Z&auml;tterstr&ouml;m U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope 2008; 118:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/13\">",
"      Rusthoven K, Chen C, Raben D, Kavanagh B. Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis. Int J Radiat Oncol Biol Phys 2008; 71:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/14\">",
"      Miyahara H, Sato T, Yoshino K. Radiation-induced cancers of the head and neck region. Acta Otolaryngol Suppl 1998; 533:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/15\">",
"      Stewart FA. Re-treatment after full-course radiotherapy: is it a viable option? Acta Oncol 1999; 38:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/16\">",
"      Duprez F, Madani I, Bonte K, et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol 2009; 93:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/17\">",
"      Dequanter D, Shahla M, Lardinois I, et al. Second primary lung malignancy in head and neck cancer patients. Eur Ann Otorhinolaryngol Head Neck Dis 2011; 128:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/18\">",
"      Chen MC, Huang WC, Chan CH, et al. Impact of second primary esophageal or lung cancer on survival of patients with head and neck cancer. Oral Oncol 2010; 46:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15270/abstract/19\">",
"      Jayaprakash V, Cheng C, Reid M, et al. Previous head and neck cancers portend poor prognoses in lung cancer patients. Ann Thorac Surg 2011; 92:1056.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3405 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15270=[""].join("\n");
var outline_f14_58_15270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345501674\">",
"      Second primary vs locoregional recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345501689\">",
"      Time to occurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H345501696\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1967057\">",
"      ACKNOWLEDGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19017?source=related_link\">",
"      Chemoprevention in oral dysplasia and head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=related_link\">",
"      Reirradiation for locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9559?source=related_link\">",
"      Treatment of locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_58_15271="Treatment of pancreas divisum";
var content_f14_58_15271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pancreas divisum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15271/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15271/contributors\">",
"     Evan Fogel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15271/contributors\">",
"     Stuart Sherman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15271/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15271/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15271/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15271/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/58/15271/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreas divisum is the most common congenital pancreatic anomaly, occurring in approximately 7 percent of subjects in autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is usually diagnosed during endoscopic retrograde cholangiopancreatography (ERCP), although magnetic resonance cholangiopancreatography (MRCP), especially with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation, can detect more than 90 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. More than 95 percent of patients with pancreatic divisum are asymptomatic and it remains controversial whether the symptoms that occur in the remaining patients are etiologically related to pancreas divisum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3431?source=see_link\">",
"     \"Anatomy and clinical significance of pancreas divisum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We believe that there is a group of patients with pancreas divisum who are subject to recurrent bouts of pancreatitis. Why such patients are at increased risk for recurrent pancreatitis is not well understood. In some, the minor papilla orifice may be so small that excessively high intrapancreatic dorsal ductal pressure occurs during active secretion, which may result in inadequate drainage, ductal distension, pain, and, in some cases, pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/5\">",
"     5",
"    </a>",
"    ]. It is possible that pancreas divisum can lead to chronic pancreatitis or \"pancreatic\" pain. Genetic studies have also suggested that as many as 10 to 20 percent of patients with pancreas divisum who have pancreatitis carry at least one allele of the cystic fibrosis gene product, suggesting a multifactorial origin of pancreatitis in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the two major therapeutic issues in symptomatic patients with pancreas divisum: the detection of pathologic minor papilla narrowing and the techniques and results of surgical and endoscopic approaches to correct the minor papilla narrowing. The anatomy and controversies surrounding the clinical significance of pancreas divisum are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3431?source=see_link\">",
"     \"Anatomy and clinical significance of pancreas divisum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DETECTION OF PATHOLOGIC MINOR PAPILLA NARROWING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The important diagnostic issue in a patient with pancreas divisum and pancreatic symptoms is whether there is remediable papillary narrowing. A number of methods have been used in an attempt to identify patients with pathologic papillary narrowing. These tests attempt to demonstrate dorsal duct dilation, papillary narrowing, increased papillary or ductal pressure, or the selective occurrence of pancreatitis in the dorsal as opposed to the ventral portion of the pancreas (",
"    <a class=\"graphic graphic_table graphicRef69143 \" href=\"UTD.htm?14/51/15164\">",
"     table 1",
"    </a>",
"    ). The sensitivity and specificity of these tests are largely undefined and correlation with a response to therapy has not been clearly shown in most studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Computerized tomography scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard computed tomography (CT) scan of the pancreas may identify dilation of the dorsal duct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    changes of chronic pancreatitis that are confined to the dorsal area of the pancreas. More commonly, the CT scan just shows nonspecific prominence of the pancreatic head and is not of diagnostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/7\">",
"     7",
"    </a>",
"    ]. Visualization of a fat plane between the dorsal and ventral portions can suggest pancreas divisum but does not generally separate symptomatic from coincidental states [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Secretin ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pancreas shows dilation of the main pancreatic duct over a 5- to 10-minute interval after intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/9\">",
"     9",
"    </a>",
"    ]. Using transcutaneous ultrasonography to monitor dorsal duct diameter, several investigators have observed that patients with pancreatic outlet obstruction may have dorsal duct dilation, which persists for more than 15 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, the precise criteria for a positive test remain undefined.",
"   </p>",
"   <p>",
"    Other series have attempted unsuccessfully to correlate the dorsal duct response on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    ultrasonography with clinical evidence of pancreatitis or dorsal ductography abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. One study correlated the outcome after accessory minor papilla sphincteroplasty with ultrasound findings in 88 patients at a mean follow-up of 53 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients with a positive test (prolonged duct dilatation for 15 to 30 minutes) had a 92 percent chance of obtaining clinical relief with minor papilla therapy compared to only 40 percent of those with normal tests (no abnormal dilation). This study suggests that the test predicts patient outcome. While one might infer from these data that secretin ultrasonography results may determine whether pancreas divisum is the etiologic factor in a particular case or just coincidental (based on ultimate response to therapy), confirmation of these results is needed.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    ultrasonography may also be problematic in patients with chronic pancreatitis. Such patients may have hyposecretory exocrine function and may not manifest dorsal duct dilation even in the presence of significant minor papilla narrowing.",
"   </p>",
"   <p>",
"    If obesity or overlying gas preclude standard transcutaneous ultrasonography, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    test can be performed under endoscopic ultrasonography observation or even CT scan observation. The role of magnetic resonance cholangiopancreatography (MRCP) for this indication is undergoing investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnostic endoscopic retrograde cholangiopancreatography (ERCP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic ventral and dorsal ductography may provide additional clues to the presence of pathologic minor papilla narrowing. An abnormal dorsal ductogram (dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    changes of chronic pancreatitis) in combination with a normal ventral duct suggests pathologic minor papilla narrowing. Dorsal duct dilation is a relatively uncommon finding and in one study was present without a ventral abnormality in 5 of 27 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/11\">",
"     11",
"    </a>",
"    ]. The frequency of an abnormality clearly correlates with the indication for the procedure. Pain provocation during dorsal ductography occasionally occurs but is of uncertain significance.",
"   </p>",
"   <p>",
"    One study observed cystic dilation of the very terminal portion of the dorsal duct in 4 of 44 patients, and coined the term \"Santorinicele\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/13\">",
"     13",
"    </a>",
"    ]. In many of these cases, the minor papilla orifice was pinpoint in size and had a web-like surface. These findings are most likely when the minor papilla is located in a diverticulum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Special ERCP techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of special and therapeutic ERCP techniques which have been used to evaluate potential minor papillary narrowing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pancreatic juice collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in the setting of normal ventral and dorsal ductography, evidence for chronic pancreatitis can be obtained by collection of pure pancreatic juice, especially from the dorsal duct. A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -stimulated bicarbonate concentration collected from the minor papilla of less than 105",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    and pancreatic juice volume of less than 3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    support a diagnosis of chronic pancreatitis. Although data supporting such an approach have involved sampling of pancreatic juice from the major papilla, we believe that they can be extrapolated to the minor papilla. In particular, we believe that the demonstration of chronic pancreatitis based upon such sampling of pancreatic juice from the minor papilla may predict less of a response to endoscopic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34201?source=see_link\">",
"     \"Pancreatic exocrine function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Papillary manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manometry of the minor papilla has been performed infrequently and normal minor papilla basal pressures have not been defined. If a basal pressure of &gt;40 mmHg is abnormal for the major papilla, use of this number for the minor papilla may also be appropriate. Our own limited experience with use of a standard 5 Fr triple lumen manometry catheter (over a 0.018 inch guidewire) in previously untreated minor papillae has invariably shown very high basal pressures of &gt;200 mmHg.",
"   </p>",
"   <p>",
"    Other studies have found high intraductal basal pressures in the dorsal duct of patients with pancreas divisum compared to accessory duct pressures (minor papilla cannulation) in non-divisum patients with patent major papilla orifices [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/14\">",
"     14",
"    </a>",
"    ]. However, these studies were not performed with small-caliber catheters and both intraductal and intrapapillary (intrasphincter) pressure were not measured.",
"   </p>",
"   <p>",
"    Once a guidewire has been passed into the dorsal duct, observation of the degree of resistance to passage of a 3, 4, or 5 Fr catheter may be a gauge of the degree of minor papilla narrowing. Although this method has not been standardized, it is similar to an intraoperative assessment used by surgeons to evaluate sphincter patency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Therapeutic trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlargement of the orifice of the minor papilla with dilation, stenting, or sphincterotomy may give helpful information in patients with daily or weekly symptoms. A response to therapy strongly implies that the minor papilla was too narrow [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short-term improvement may be due to a placebo effect. In patients with infrequent bouts of pancreatitis (eg, one to two times per year) several years of observation may be required before determining the benefits of trial therapy. However, long intervals of trial stenting are not currently recommended because of potential adverse effects. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Endoscopic minor papilla dilation and stenting'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intraoperative patency determination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the surgeon determined patency of the minor papilla by assessing the resistance to passage of a 0.030 inch (0.75 mm) diameter lacrimal probe into the minor papilla. This approach requires laparotomy and duodenotomy. These observations correlate with the endoscopic findings that minor papilla cannulation with guidewires greater than 0.021 inch in diameter is usually difficult.",
"   </p>",
"   <p>",
"    In one study, patients with minor papilla narrowing by lacrimal probe patency had a high probability of response to therapy, whereas patients with patent minor papilla by lacrimal probe patency had a low probability of responding to minor papilla sphincteroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/10\">",
"     10",
"    </a>",
"    ]. The surgeon may also find changes of chronic pancreatitis limited to the dorsal pancreas, a finding suggestive of minor papilla disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SURGICAL AND ENDOSCOPIC MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of uncertainty about the importance of pancreas divisum as a causative factor in acute or chronic pancreatitis or chronic abdominal pain, most endoscopists are cautious and conservative in their approach. As will be seen, the greatest likelihood of a response occurs in patients with recurrent episodes of apparently idiopathic acute pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of minor papilla narrowing in pancreas divisum has traditionally been approached surgically. However, similar results are being obtained in experienced centers with endoscopic approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgical minor papilla sphincterotomy and sphincteroplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of relatively small studies have been published which evaluated the results of surgical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. Most surgeons also include a cholecystectomy and major papilla sphincteroplasty, thereby making pathophysiologic interpretation less precise. The overall success rate in a combined series of 198 patients was 74 percent. The results varied with the clinical condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with attacks of acute recurrent pancreatitis or epigastric pain experienced the greatest rate of improvement (83 percent).",
"     </li>",
"     <li>",
"      Patients with established chronic pancreatitis or those with chronic continuous pain had a lower response: 59 percent of those with pain alone improved while none of the four with chronic pancreatitis experienced a significant response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study prospectively evaluated the effects of sphincteroplasty of the accessory duct in 37 patients with pancreas divisum and acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/16\">",
"     16",
"    </a>",
"    ]. Surgery was successful in 84 percent of patients for the long-term prevention of recurrent acute pancreatitis but was significantly less successful in eliminating \"pancreatic\" pain.",
"   </p>",
"   <p>",
"    Series of surgical sphincterotomy and sphincteroplasty seem to have similar outcomes. The results are generally excellent if appropriate patients are selected. Reporting of complications from surgery has not been standardized, but the morbidity rate is approximately 10 percent, the rate of major complications is about 4 percent, and the restenosis rate is approximately 8 percent. Postoperative deaths have occurred.",
"   </p>",
"   <p>",
"    Other surgical procedures have been used in selected cases. Patients with obviously dilated dorsal ducts may be candidates for a Puestow procedure (lateral pancreaticojejunostomy). Severely symptomatic patients who fail to respond to duct decompression may be candidates for pancreatic denervation or resection, but results from both are variable. Total pancreatectomy has controlled incapacitating pain in a limited number of patients but severe maldigestion and diabetes mellitus are inevitable complications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/11\">",
"     11",
"    </a>",
"    ]. Salvaging and reinfusion of the islet cells or autotransplantation, is now an available alternative, with promising results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endoscopic minor papilla dilation and stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dilation of the narrowed minor papilla can be achieved by passage of a tapered-tipped dilating catheter (5 to 10 Fr) over a guidewire or by passage of a small diameter balloon (4 to 5 mm) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there is significant concern that balloon dilation may provoke tissue disruption and serious pancreatitis; as a result, these techniques are generally not recommended.",
"   </p>",
"   <p>",
"    A prospective, randomized trial compared long-term dorsal duct stenting to continued conservative therapy in 19 patients with pancreas divisum with idiopathic recurrent pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/18\">",
"     18",
"    </a>",
"    ]. The stents (3 to 7 cm long with multiple side-holes) were exchanged every three to four months and were left in place for one year. The stented patients had a much higher rate of improvement (90 versus 11 percent) due to statistically significantly reductions in hospitalizations, emergency department visits, and pancreatitis episodes. These benefits generally persisted over a mean 24-month follow-up period after stent removal. Similar conclusions have been reached in other uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, prolonged pancreatic stenting is associated with a variety of complications including stent occlusion or migration, pancreatitis, pancreatic duct perforation, and pseudocyst formation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. A major concern in treating minor papilla stenosis with long-term stenting is the induction of ductal and parenchymal changes indicating or simulating chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. In one study of 25 patients undergoing short-term pancreatic duct stenting, ductal and parenchymal changes were seen in over 50 percent when evaluated by endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound at the time of stent removal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/27\">",
"     27",
"    </a>",
"    ]. Among four patients who had parenchymal changes at the time of stent removal, two had new changes suggestive of focal chronic pancreatitis in the stented regions.",
"   </p>",
"   <p>",
"    Because of these observations, prolonged stent therapy remains largely experimental and is",
"    <strong>",
"     not",
"    </strong>",
"    generally recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=see_link\">",
"     \"Overview of pancreatic stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endoscopic minor papilla sphincterotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic sphincterotomy is receiving increased application for opening the minor papilla. (The term papillotomy may be preferred since a true sphincter may not be present.) Two techniques have generally been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial dilation of the orifice to 5 to 7 Fr followed by a mini-papillotome or standard papillotome (generally wire-guided) to make a 4 to 6 mm incision in approximately the 10 to 12 o'clock position.",
"     </li>",
"     <li>",
"      Placement of a 3 to 4 Fr plastic stent, followed by a needle-knife cut, generally in the 10 to 12 o'clock position to a depth of 3 to 4 mm and a height of 4 to 6 mm, using the stent as a guide [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/28\">",
"       28",
"      </a>",
"      ]. Unfortunately, the landmarks for determining the appropriate depth and height of the cuts have not been precisely defined, except in Santorinicele patients in whom unroofing of the bulbous segment is the goal. We prefer a 4 to 8 cm stent length for 3 to 4 Fr stents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We and other groups have found pull sphincterotomy and needle-knife technique to be equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. As an alternative, placement of a stent without an internal flange will often result in spontaneous passage of the stent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/31\">",
"     31",
"    </a>",
"    ]. In patients with a Santorinicele or a very dilated dorsal duct, sphincterotomy without stenting may be adequate.",
"   </p>",
"   <p>",
"    Several small series with brief follow-up have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/29,32-34\">",
"     29,32-34",
"    </a>",
"    ]. Using a global pain score method, endoscopic results parallel those of surgery. However, recall bias and prior minor papilla therapy in a number of patients may have influenced these results. In addition, with relatively short-term follow-up, considering a patient \"improved\" might be premature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 75 percent of patients with pancreas divisum who have idiopathic acute recurrent pancreatitis are improved after endoscopic therapy. Patients who are improved have fewer pancreatitis attacks and hospitalizations.",
"     </li>",
"     <li>",
"      Among patients with chronic pancreatitis or pain suggestive of pancreatic origin but no other documented evidence of pancreatic disease, approximately 50 percent experience some pain reduction, but only 25 percent have at least a 50 percent pain improvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective, randomized study of 33 pancreas divisum patients with pain but no documented pancreatitis, there was a trend toward benefit (50 percent pain improvement) with treatment (44 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/35\">",
"     35",
"    </a>",
"    ]. A larger series of patients is needed to confirm this benefit.",
"   </p>",
"   <p>",
"    These observations indicate that less than one-half of pain syndrome patients benefit from intervention. However, in truly disabled patients, the 40 to 50 percent chance of pain improvement may justify a trial therapy. The main indication for endoscopic sphincterotomy is in patients with recurrent episodes of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk-benefit ratio should be carefully reviewed with patients considered for endoscopic therapy. The magnitude of the short-term complication rate for endoscopic minor papilla sphincterotomy has been suboptimally quantified, as experience remains limited and reports have come only from experienced centers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/36\">",
"     36",
"    </a>",
"    ]. In the largest series to date of patients with pancreas divisum undergoing ERCP, the overall post-ERCP pancreatitis rate was 6.8 percent (187 of 2753) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/37\">",
"     37",
"    </a>",
"    ]. However, comparing four distinct risk categories (no attempt made at minor papilla cannulation, attempted minor papilla cannulation with pancreatogram only, attempted minor papilla cannulation with further manipulation, and minor papilla cannulation with sphincterotomy), rates of post-ERCP pancreatitis were 1.2 percent (8 of 632), 5.9 percent (69 of 1165), 8.2 percent (174 of 2121), and 10.6 percent (105 of 987), respectively (p &lt;.05).",
"   </p>",
"   <p>",
"    The restenosis rate for any therapy of the minor papilla is estimated to be 10 to 20 percent, although methods of calibration of restenosis are uncertain. Our experience is similar to that of others in that patients who develop restenosis after endoscopic sphincterotomy also restenose after sphincteroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/38\">",
"     38",
"    </a>",
"    ]. Trials of injection of long-acting steroids around the sphincterotomy are underway in an effort to limit restenosis.",
"   </p>",
"   <p>",
"    High-grade strictures of the terminal 10 mm of the dorsal duct are estimated to occur in 2 to 3 percent of patients. These strictures are a particular problem since the narrowing extends beyond the duodenal wall and a pancreatic head resection or a Puestow drainage procedure may be required.",
"   </p>",
"   <p>",
"    Lifelong follow-up is required for both surgical and endoscopic treatments. Similar techniques are now being applied to children in whom long-term outcomes are especially important [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15271/abstract/39\">",
"     39",
"    </a>",
"    ]. As with pancreatic stenting, pancreatic sphincterotomy should be restricted to large centers with extensive experience in therapeutic ERCP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pancreas divisum is the most common congenital pancreatic anomaly, occurring in approximately 7 percent of subjects in autopsy series.",
"     </li>",
"     <li>",
"      More than 95 percent of patients with pancreas divisum are asymptomatic and it remains controversial whether the symptoms that occur in the remaining patients are etiologically related to pancreas divisum. We believe that there is a group of patients with pancreas divisum who are subject to recurrent bouts of pancreatitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The important diagnostic issue in a patient with pancreas divisum and pancreatic symptoms is whether there is remediable papillary narrowing. A number of methods have been used in an attempt to identify patients with pathologic papillary narrowing (",
"      <a class=\"graphic graphic_table graphicRef69143 \" href=\"UTD.htm?14/51/15164\">",
"       table 1",
"      </a>",
"      ). The sensitivity and specificity of these tests are largely undefined and correlation with a response to therapy has not been clearly shown in most studies. However, a finding of a dilated dorsal duct or isolated changes of chronic pancreatitis in the dorsal system (ie, with a normal ventral duct) suggests pathologic narrowing of the minor papilla. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Detection of pathologic minor papilla narrowing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of minor papilla narrowing in pancreas divisum has traditionally been approached surgically. However, similar results are being obtained in experienced centers with endoscopic approaches. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Surgical minor papilla sphincterotomy and sphincteroplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our decision to intervene with endoscopic therapy typically follows a thoroughly negative evaluation (history, physical examination, laboratory testing including genetic evaluation, autoimmune markers, etc), and a discussion with the individual patient regarding the potential benefits versus risks of minor papilla therapy (both short- and long-term). Because of uncertainty about the importance of pancreas divisum as a causative factor in acute or chronic pancreatitis or chronic abdominal pain, most endoscopists are cautious and conservative in their approach. The greatest likelihood of a response occurs in patients with recurrent episodes of apparently idiopathic acute pancreatitis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Endoscopic minor papilla dilation and stenting'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Endoscopic minor papilla sphincterotomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/1\">",
"      Smanio T. Proposed nomenclature and classification of the human pancreatic ducts and duodenal papillae. Study based on 200 post mortems. Int Surg 1969; 52:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/2\">",
"      Stimec B, Bulaji�� M, Korneti V, et al. Ductal morphometry of ventral pancreas in pancreas divisum. Comparison between clinical and anatomical results. Ital J Gastroenterol 1996; 28:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/3\">",
"      Matos C, Metens T, Devi&egrave;re J, et al. Pancreas divisum: evaluation with secretin-enhanced magnetic resonance cholangiopancreatography. Gastrointest Endosc 2001; 53:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/4\">",
"      Manfredi R, Costamagna G, Brizi MG, et al. Pancreas divisum and \"santorinicele\": diagnosis with dynamic MR cholangiopancreatography with secretin stimulation. Radiology 2000; 217:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/5\">",
"      Lehman GA, Sherman S. Pancreas divisum. Diagnosis, clinical significance, and management alternatives. Gastrointest Endosc Clin N Am 1995; 5:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/6\">",
"      Gelrud A, Sheth S, Banerjee S, et al. Analysis of cystic fibrosis gener product (CFTR) function in patients with pancreas divisum and recurrent acute pancreatitis. Am J Gastroenterol 2004; 99:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/7\">",
"      Lindstr&ouml;m E, Ihse I. Computed tomography findings in pancreas divisum. Acta Radiol 1989; 30:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/8\">",
"      Zeman RK, McVay LV, Silverman PM, et al. Pancreas divisum: thin-section CT. Radiology 1988; 169:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/9\">",
"      Tulassay Z, Jakab Z, Vad&agrave;sz A, et al. Secretin provocation ultrasonography in the diagnosis of papillary obstruction in pancreas divisum. Gastroenterol J 1991; 51:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/10\">",
"      Warshaw AL, Simeone JF, Schapiro RH, Flavin-Warshaw B. Evaluation and treatment of the dominant dorsal duct syndrome (pancreas divisum redefined). Am J Surg 1990; 159:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/11\">",
"      Lindstr&ouml;m E, Ihse I. Dynamic CT scanning of pancreatic duct after secretin provocation in pancreas divisum. Dig Dis Sci 1990; 35:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/12\">",
"      Lowes JR, Lees WR, Cotton PB. Pancreatic duct dilatation after secretin stimulation in patients with pancreas divisum. Pancreas 1989; 4:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/13\">",
"      Eisen G, Schutz S, Metzler D, et al. Santorinicele: new evidence for obstruction in pancreas divisum. Gastrointest Endosc 1994; 40:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/14\">",
"      Staritz M, Meyer zum B&uuml;schenfelde KH. Elevated pressure in the dorsal part of pancreas divisum: the cause of chronic pancreatitis? Pancreas 1988; 3:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/15\">",
"      Madura JA. Pancreas divisum: stenosis of the dorsally dominant pancreatic duct. A surgically correctable lesion. Am J Surg 1986; 151:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/16\">",
"      Bradley EL 3rd, Stephan RN. Accessory duct sphincteroplasty is preferred for long-term prevention of recurrent acute pancreatitis in patients with pancreas divisum. J Am Coll Surg 1996; 183:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/17\">",
"      Guelrud M, Mendoza S, Viera L, Gelrud D. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 1991; 37:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/18\">",
"      Lans JI, Geenen JE, Johanson JF, Hogan WJ. Endoscopic therapy in patients with pancreas divisum and acute pancreatitis: a prospective, randomized, controlled clinical trial. Gastrointest Endosc 1992; 38:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/19\">",
"      Ertan A. Long-term results after endoscopic pancreatic stent placement without pancreatic papillotomy in acute recurrent pancreatitis due to pancreas divisum. Gastrointest Endosc 2000; 52:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/20\">",
"      Heyries L, Barthet M, Delvasto C, et al. Long-term results of endoscopic management of pancreas divisum with recurrent acute pancreatitis. Gastrointest Endosc 2002; 55:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/21\">",
"      Ikenberry SO, Sherman S, Hawes RH, et al. The occlusion rate of pancreatic stents. Gastrointest Endosc 1994; 40:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/22\">",
"      Johanson JF, Schmalz MJ, Geenen JE. Incidence and risk factors for biliary and pancreatic stent migration. Gastrointest Endosc 1992; 38:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/23\">",
"      Johanson JF, Schmalz MJ, Geenen JE. Simple modification of a pancreatic duct stent to prevent proximal migration. Gastrointest Endosc 1993; 39:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/24\">",
"      Kozarek RA. Pancreatic stents can induce ductal changes consistent with chronic pancreatitis. Gastrointest Endosc 1990; 36:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/25\">",
"      Smith MT, Sherman S, Ikenberry SO, et al. Alterations in pancreatic ductal morphology following polyethylene pancreatic stent therapy. Gastrointest Endosc 1996; 44:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/26\">",
"      Sherman S, Alvarez C, Robert M, et al. Polyethylene pancreatic duct stent-induced changes in the normal dog pancreas. Gastrointest Endosc 1993; 39:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/27\">",
"      Sherman S, Hawes RH, Savides TJ, et al. Stent-induced pancreatic ductal and parenchymal changes: correlation of endoscopic ultrasound with ERCP. Gastrointest Endosc 1996; 44:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/28\">",
"      Siegel JH, Cohen SA, Kasmin FE, Veerappan A. Stent-guided sphincterotomy. Gastrointest Endosc 1994; 40:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/29\">",
"      Lehman GA, Sherman S, Nisi R, Hawes RH. Pancreas divisum: results of minor papilla sphincterotomy. Gastrointest Endosc 1993; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/30\">",
"      Attwell A, Borak G, Hawes R, et al. Endoscopic pancreatic sphincterotomy for pancreas divisum by using a needle-knife or standard pull-type technique: safety and reintervention rates. Gastrointest Endosc 2006; 64:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/31\">",
"      Rashdan A, Fogel EL, McHenry L Jr, et al. Improved stent characteristics for prophylaxis of post-ERCP pancreatitis. Clin Gastroenterol Hepatol 2004; 2:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/32\">",
"      Coleman SD, Eisen GM, Troughton AB, Cotton PB. Endoscopic treatment in pancreas divisum. Am J Gastroenterol 1994; 89:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/33\">",
"      Liguory C, Lefebvre JF, Canard JM, et al. [Pancreas divisum: clinical and therapeutic study in man. Apropos of 87 cases]. Gastroenterol Clin Biol 1986; 10:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/34\">",
"      Chacko LN, Chen YK, Shah RJ. Clinical outcomes and nonendoscopic interventions after minor papilla endotherapy in patients with symptomatic pancreas divisum. Gastrointest Endosc 2008; 68:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/35\">",
"      Sherman S, Hawes R, Nisi R, et al. Randomized controlled trial of minor papilla sphincterotomy (MiES) in pancreas divisum (Pdiv) patients with pain only. Gastrointest Endosc 1994; 40:125P.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/36\">",
"      Sherman S, Lehman GA. Endoscopic pancreatic sphincterotomy: techniques and complications. Gastrointest Endosc Clin N Am 1998; 8:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/37\">",
"      Moffatt DC, Cot&eacute; GA, Avula H, et al. Risk factors for ERCP-related complications in patients with pancreas divisum: a retrospective study. Gastrointest Endosc 2011; 73:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/38\">",
"      Kozarek RA, Ball TJ, Patterson DJ, et al. Endoscopic approach to pancreas divisum. Dig Dis Sci 1995; 40:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15271/abstract/39\">",
"      Wagner CW, Golladay ES. Pancreas divisum and pancreatitis in children. Am Surg 1988; 54:22.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5645 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15271=[""].join("\n");
var outline_f14_58_15271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DETECTION OF PATHOLOGIC MINOR PAPILLA NARROWING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Computerized tomography scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Secretin ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnostic endoscopic retrograde cholangiopancreatography (ERCP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Special ERCP techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pancreatic juice collection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Papillary manometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Therapeutic trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intraoperative patency determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SURGICAL AND ENDOSCOPIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgical minor papilla sphincterotomy and sphincteroplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endoscopic minor papilla dilation and stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endoscopic minor papilla sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5645\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5645|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/51/15164\" title=\"table 1\">",
"      Detection of pathologic minor papilla narrowing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3431?source=related_link\">",
"      Anatomy and clinical significance of pancreas divisum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42072?source=related_link\">",
"      Overview of pancreatic stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34201?source=related_link\">",
"      Pancreatic exocrine function tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_58_15272="Epidemiology of influenza";
var content_f14_58_15272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of influenza",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15272/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15272/contributors\">",
"     Raphael Dolin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15272/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15272/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15272/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/58/15272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza occurs in distinct outbreaks of varying extent every year. This epidemiologic pattern reflects the changing nature of the antigenic properties of influenza viruses, and their subsequent spread depends upon multiple factors, including transmissibility of the virus and the susceptibility of the population. Influenza A viruses, in particular, have a remarkable ability to undergo periodic changes in the antigenic characteristics of their envelope glycoproteins, the hemagglutinin and the neuraminidase.",
"   </p>",
"   <p>",
"    Influenza hemagglutinin is a surface glycoprotein that binds to sialic acid residues on respiratory epithelial cell surface glycoproteins. This interaction is necessary for the initiation of infection. After viral replication, progeny virions are also bound to the host cell. Neuraminidase cleaves these links and liberates the new virions; it also counteracts hemagglutinin-mediated self-aggregation entrapment in respiratory secretions.",
"   </p>",
"   <p>",
"    Among influenza A viruses that infect humans, three major subtypes of hemagglutinins (H1, H2, and H3) and two subtypes of neuraminidases (N1 and N2) have been described. Influenza B viruses have a lesser propensity for antigenic changes, and only antigenic drifts in the hemagglutinin have been described.",
"   </p>",
"   <p>",
"    The epidemiology of influenza, including morbidity and mortality, will be reviewed here. The clinical manifestations, complications, diagnosis, prevention, and treatment of this infection are discussed separately; the epidemiology of pandemic H1N1 influenza (\"swine influenza\") and avian influenza are also presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=see_link\">",
"     \"Diagnosis of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1200927955\">",
"    <span class=\"h1\">",
"     DEFINITION OF ANTIGENIC SHIFTS AND DRIFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major changes in the envelope glycoproteins, the hemagglutinin and the neuraminidase, are referred to as antigenic shifts, and minor changes are called antigenic drifts. Antigenic shifts are associated with epidemics and pandemics of influenza A, whereas antigenic drifts are associated with more localized outbreaks of varying extent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIGENIC SHIFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza viruses have a segmented genome that can result in high rates of reassortment among viruses coinfecting the same cell. Reassortment between animal and human viruses may result in the emergence of pandemic strains (",
"    <a class=\"graphic graphic_table graphicRef52181 \" href=\"UTD.htm?15/58/16300\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Such reassortment events led to the emergence of the viruses that caused the pandemics of 1957, 1968, and 2009. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Reassortment between different influenza viruses does not always result in a pandemic. As an example, a novel reassortant strain of influenza A H1N2 viruses appeared in humans in the 2001 to 2002 season in North America, Europe, the Middle East, and Southeast Asia, and caused seasonal epidemics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was concern that reassortment between human and avian influenza viruses might have occurred when avian influenza",
"    <span class=\"nowrap\">",
"     A/H5N1",
"    </span>",
"    infections were detected in humans in Hong Kong in March 1997 at the time of an extensive outbreak of avian influenza",
"    <span class=\"nowrap\">",
"     A/H5N1",
"    </span>",
"    in poultry. However, such a reassortant virus was not found. Nevertheless, the potential for such reassortment remains a concern, given the high mortality of avian influenza",
"    <span class=\"nowrap\">",
"     A/H5N1",
"    </span>",
"    infections in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many historians agree that the first recognition of an influenza pandemic was in 1510 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/6\">",
"     6",
"    </a>",
"    ]. In more recent history, the 1918 influenza was particularly severe and widespread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pandemic of 1918",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extremely severe and extensive pandemic of 1918 and 1919 (swine influenza or Spanish influenza) was associated with the emergence of antigenic shifts in both the hemagglutinin (H1) and the neuraminidase (N1) of influenza A [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/7\">",
"     7",
"    </a>",
"    ]. The pathogenicity of this virus has been well-characterized. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other pandemics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1957, the shift to H2 and N2 resulted in a severe pandemic.",
"     </li>",
"     <li>",
"      In 1968, an antigenic shift occurred that involved only the hemagglutinin (from H2N2 to H3N2); the resulting pandemic was less extensive than that seen in 1957 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1977, an influenza A virus emerged that had shifted to H1N1. The resulting pandemic affected primarily young individuals who lacked preexisting immunity to H1N1 (ie, those born after H1N1 viruses had last circulated from 1918 to 1957).",
"      <br/>",
"      <br/>",
"      Since 1977,",
"      <span class=\"nowrap\">",
"       A/H1N1",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       A/H3N2",
"      </span>",
"      subtypes along with influenza B viruses have frequently circulated at the same time [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The emergence of a novel H1N1 human-swine-avian reassortant virus in March 2009 in North America resulted in a pandemic, and the pandemic H1N1 virus has continued to circulate since then. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link\">",
"       \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104949276\">",
"    <span class=\"h2\">",
"     H3N2 variant influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since July 2011, the United States Centers for Diseases Control and Prevention (CDC) has reported over 300 cases of H3N2 variant (H3N2v) influenza A infection caused by reassortment of swine-origin H3N2 influenza A viruses and 2009 pandemic H1N1 influenza A viruses, most of which have occurred since July 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/10-18\">",
"     10-18",
"    </a>",
"    ]. The H3N2vinfluenza virus contains the M gene from 2009 pandemic H1N1 influenza A virus, which may confer increased transmissibility to and among humans compared with other swine-origin influenza viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/14\">",
"     14",
"    </a>",
"    ]. However, sustained human-to-human transmission of this strain has not been observed. The majority of cases in 2012 have been reported in Indiana and Ohio, but cases have also been reported in several other states. Almost all patients reported direct or indirect contact with swine, and the majority attended fairs where swine were present. Most patients have had mild illness. Updated case counts can be found on the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm\">",
"     CDC&rsquo;s web site",
"    </a>",
"    .",
"    <br/>",
"    <br/>",
"    The CDC has issued recommendations for the prevention of transmission of H3N2v influenza, which include frequent handwashing and avoidance of contact with pigs that appear ill [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, individuals at high risk for influenza complications (eg, individuals &lt;5 or &ge;65 years of age, pregnant women, and individuals with certain chronic medical conditions) should consider avoiding exposure to pigs and swine barns, especially if sick pigs have been identified. Further recommendations can be found on the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm\">",
"     CDC&rsquo;s web site",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The viruses are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    , but resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Choice of antiviral drug'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In a study that evaluated levels of cross-reactive antibodies to H3N2v influenza by age, no children &lt;5 years of age and fewer than 20 percent of individuals aged &le;14 years or &ge;40 years of age had seroprotective titers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/19\">",
"     19",
"    </a>",
"    ]. However, approximately half of individuals between the ages of 15 and 39 years of age had seroprotective titers. Receipt of the seasonal influenza vaccine did not provide substantial rates of seroprotection against these strains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H3#H3\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Antigenic composition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTIGENIC DRIFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between the years of antigenic shifts, antigenic drifts have occurred almost annually and have resulted in outbreaks of variable extent and severity. Outbreaks due to antigenic drifts are usually less extensive and severe than the epidemics or pandemics associated with antigenic shifts. Antigenic drifts are believed to result from point mutations in the RNA gene segments that code for the hemagglutinin or the neuraminidase; they are thought to occur sequentially as the virus spreads through a susceptible population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/20\">",
"     20",
"    </a>",
"    ]. Changes in the hemagglutinin that result in antigenic shifts are of such great magnitude that they cannot be accounted for by point mutations alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extremely severe and extensive pandemic of 1918 and 1919 resulted in 50 to 100 million deaths worldwide and was exceptional in the high death rates that were seen among healthy adults aged 15 to 34 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A similarly high death rate has not occurred in this age group in either prior or subsequent influenza A pandemics or epidemics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenicity of the hemagglutinin of the 1918 pandemic virus was directly demonstrated in a mouse model using genetic recombination techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Researchers constructed influenza viruses using hemagglutinin alone or hemagglutinin with neuraminidase from the pandemic strain. Both recombinant viruses led to widespread infection of the lungs, suggesting that hemagglutinin conferred enhanced pathogenicity in mice. Furthermore, these recombinant viruses could induce high levels of chemokines and cytokines, resulting in inflammatory cell infiltration and severe hemorrhage that were characteristic of the illness seen during the pandemic.",
"     </li>",
"     <li>",
"      Scientists used reverse genetics to create an influenza virus with all eight gene segments of the 1918 pandemic strain in order to study its virulence in animal models [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/25\">",
"       25",
"      </a>",
"      ]. After infection, the 1918 strain produced 39,000 times more virus particles in the lungs of mice compared with more contemporary H1N1 influenza strains. Furthermore, the ability of an influenza virus to replicate in the absence of protease is thought to be a critical determinant of pathogenicity in animal models; the 1918 strain was able to replicate equally well in the absence or presence of trypsin in vitro.",
"     </li>",
"     <li>",
"      Scientists have fully sequenced the entire genome of the 1918 strain, which has given insight into the origins of the virus [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/26\">",
"       26",
"      </a>",
"      ]. In the pandemics of 1957 and 1968, two to three gene segments from avian strains combined with the circulating human strain to form a reassortant virus. The influenza virus that caused the 2009 pandemic was caused by a quadruple reassortment of two swine strains, one human strain, and one avian strain. In contrast, sequence and phylogenetic analyses of the 1918 virus genome suggest that it was derived wholly from an ancestor that originally infected birds and adapted to humans. Some amino acid changes identified in the 1918 strain are also seen in H5N1 and H7N7 avian viruses that have caused human fatalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link\">",
"       \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF INFLUENZA OUTBREAKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza outbreaks have a seasonal distribution and characteristic time course [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/27\">",
"     27",
"    </a>",
"    ]. Factors influencing the extent and severity of an outbreak are less clear. Two or three different influenza strains typically circulate concurrently in a given influenza season [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One factor that may influence which influenza strains will predominate during an influenza season is the seroprotection rate among children during the preceding season. In a study in which children and adults were tested for antibodies to locally circulating influenza strains during three consecutive influenza seasons (2006-2007, 2007-2008, and 2008-2009), the lowest rates of seroprotection in children (but not in adults) coincided with the dominant influenza subtype during the following winter epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/29\">",
"     29",
"    </a>",
"    ]. The authors suggest that the protection rate in children is important for shaping future epidemics because children are prolific disseminators of respiratory virus infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Seasonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks of influenza occur almost exclusively during the winter months in the northern and southern hemispheres (which occur at different times of the year). It is highly unusual to detect influenza A viruses at other times, although individual infections and even outbreaks have been reported during the warm weather months.",
"   </p>",
"   <p>",
"    Travelers to tropical regions should be reminded that influenza may occur throughout the year in the tropics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/30\">",
"     30",
"    </a>",
"    ]. In a study of laboratory-confirmed influenza virus infection from 85 countries, more than one influenza epidemic period per year was more common in tropical countries (41 percent) than in temperate countries (15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/31\">",
"     31",
"    </a>",
"    ]. Year-round activity occurred in 3 of 43 temperate countries (7 percent), 1 of 6 subtropical countries (17 percent), and 11 of 30 tropical countries (37 percent).",
"   </p>",
"   <p>",
"    In addition, summertime outbreaks of influenza have occurred on cruise ships in the northern and southern hemispheres. Volume of airline travel has been linked to transnational spread of influenza infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/32\">",
"     32",
"    </a>",
"    ]. Repeat vaccination is not necessary in travelers who received routine vaccination at the appropriate time in the previous fall or winter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations for travel\", section on 'Influenza vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=see_link&amp;anchor=H13#H13\">",
"     \"Seasonal influenza vaccination in children\", section on 'Travelers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    How influenza A virus persists between outbreaks remains poorly understood. It is possible that sporadic cases of viral infection at other times are caused by influenza but not diagnosed as such or that virus is imported from geographically distant sites, in which outbreaks are occurring, by the travel of infected individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Time course of an outbreak",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza A outbreaks typically begin abruptly, peak over a two to three week period, and last for two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/27,28,33\">",
"     27,28,33",
"    </a>",
"    ]. In most outbreaks, the earliest indication of influenza activity is an increase in febrile respiratory illnesses in children, followed by increases in influenza-like illnesses in adults. Increases in absenteeism from work and school are usually later manifestations of outbreaks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link\">",
"     \"Clinical manifestations of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most outbreaks have attack rates of 10 to 20 percent in the general population, but rates can exceed 50 percent in pandemics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/34\">",
"     34",
"    </a>",
"    ]. Extraordinarily high attack rates have been reported in institutionalized and semiclosed populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Factors determining the severity of an outbreak",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors that determine the extent and severity of outbreaks are not fully understood. The susceptibility of the population, as determined by the prevalence of antibodies to circulating virus, clearly plays a major role. Some outbreaks cease when a large pool of susceptible individuals is no longer present in the population. However, some outbreaks appear to end when a large pool of susceptible individuals still exists. It has been suggested that influenza viruses may differ in \"intrinsic virulence\" such as their efficiency of transmission or their ability to cause symptomatic infection.",
"   </p>",
"   <p>",
"    The severity of influenza outbreaks depends partly on the strain(s) of influenza virus circulating among the total population. H3N2 influenza A viruses usually cause the most severe disease, followed by influenza B viruses, and with H1N1 influenza A viruses causing the least severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. However, among young children, H1N1 influenza infections may be more severe than in older children and adults. Between 1976 and 2007, the average mortality rates in the United States for the 22 seasons during which H3N2 influenza A was a prominent strain were 2.7 times higher than for the nine seasons that it was not the major strain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/38\">",
"     38",
"    </a>",
"    ]. Seasons in which both H3N2 influenza A viruses and influenza B viruses cocirculate cause higher rates of hospitalization than otherwise expected [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTIBODY RESPONSE TO THE 1918 PANDEMIC STRAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of 32 individuals born in or before 1915, all had neutralizing antibody responses to the H1N1 influenza strain that caused the 1918 pandemic, even nine decades after its occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/39\">",
"     39",
"    </a>",
"    ]. Seven of eight individuals tested had circulating B cells that secreted antibodies that bound hemagglutinin (HA) from the 1918 pandemic influenza strain. Monoclonal antibodies that were generated from the B cells of three separate donors had potent neutralizing activity against the 1918 strain and bound to its HA protein with high affinity. They also cross-reacted with the genetically similar HA of a 1930 swine H1N1 influenza strain, but did not cross-react with HAs of more contemporary human influenza viruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY IN ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 1976 and 2007, annual influenza-associated deaths from respiratory and circulatory causes (including pneumonia and influenza) in the United States ranged from 3349 to 48,614, and the annual rate of influenza-associated deaths ranged from 1.4 to 16.7 deaths per 100,000 persons [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/38\">",
"     38",
"    </a>",
"    ]. Due at least in part to high attack rates, the morbidity caused by influenza in the general population is substantial. Among adults, increased rates of morbidity and mortality are associated with advanced age and with underlying comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza epidemics generally disproportionately affect elderly persons, with the highest rates of morbidity and mortality in this group [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/35-37,41-45\">",
"       35-37,41-45",
"      </a>",
"      ]. In a study of the National Hospital Discharge Survey database, hospitalization rates for pneumonia increased by 20 percent from 1988-1990 to 2000-2002 for patients aged 65 to 85 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/42\">",
"       42",
"      </a>",
"      ]. In addition, the risk of death during a hospitalization was 50 percent higher if the diagnosis was pneumonia compared with 10 other common reasons for admission in the elderly population. The risk of pneumonia in this age group is increased in patients with comorbid conditions, such as chronic cardiac and pulmonary diseases or diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Excess hospitalizations for patients with chronic diseases who acquire influenza infection range from approximately 20 to more than 1000 per 100,000 individuals, with the highest rates occurring in those less than five and more than 64 years of age. Similar findings were noted in a retrospective cohort study of women under the age of 65 with and without chronic medical conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/46\">",
"       46",
"      </a>",
"      ]. Rates of hospitalization for acute cardiopulmonary events and mortality were higher during the influenza season and the presence of other comorbidities increased the risk of hospitalization and death.",
"     </li>",
"     <li>",
"      Influenza vaccination was associated with a decrease in hospitalizations for cardiac disease and cerebrovascular disease among a large cohort of patients 65 years and older from three managed care groups compared to members who were not vaccinated [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/47\">",
"       47",
"      </a>",
"      ]. The mortality rate from all causes was also significantly lower among the vaccinated group. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H14#H14\">",
"       \"Seasonal influenza vaccination in adults\", section on 'Elderly patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that contribute to more severe influenza infections in elderly patients include decreased lung compliance, decreased respiratory muscle strength, declining cellular immunity, and decreased B cell responses to new antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Morbidity and mortality in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Disease burden'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mortality during influenza pandemics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although death rates from influenza are usually disproportionately higher among elderly individuals and infants during influenza epidemics, a shift in the age distribution is seen during pandemics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. During the 1918 influenza pandemic, high rates of mortality occurred not only at the extremes of age, but also in young adults between the ages of 20 and 40 years (",
"    <a class=\"graphic graphic_figure graphicRef75017 \" href=\"UTD.htm?34/44/35534\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/49\">",
"     49",
"    </a>",
"    ]. During the 2009 pandemic, high rates of morbidity and mortality were noted among children and young adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\", section on 'Morbidity and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During a pandemic, excess mortality related to influenza may be higher in the first or second season depending on geographic location [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/50\">",
"     50",
"    </a>",
"    ]. In a study using national vital statistics by age in six countries, geographical and temporal pandemic patterns in mortality were compared with the genetic drift of the",
"    <span class=\"nowrap\">",
"     A/H3N2",
"    </span>",
"    influenza viruses by analyzing hemagglutinin and neuraminidase sequences from GenBank. In North America, the majority of influenza-related deaths in 1968-1969 and 1969-1970 occurred during the first pandemic season; in contrast, mortality was delayed until the second pandemic season in Europe and Asia. This phenomenon may be due to higher preexisting neuraminidase immunity (from the",
"    <span class=\"nowrap\">",
"     A/H2N2",
"    </span>",
"    era) in Europe and Asia than in North America, combined with a subsequent drift in the neuraminidase antigen during 1969-1970.",
"   </p>",
"   <p>",
"    Many deaths during the 1918 influenza pandemic were thought to be due to secondary bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15272/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gaps in preparedness planning for pandemic influenza remain. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment and prevention of avian influenza\", section on 'Planning for a pandemic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1120576803\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-risk groups for influenza complications have been identified. These groups are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Definition of high risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1200929549\">",
"    <span class=\"h1\">",
"     INFLUENZA ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization and its reporting network, tracks influenza virus isolates throughout the world. This information, which is updated weekly during influenza season, is available via the CDC through its web site (",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/\">",
"     www.cdc.gov/flu/weekly",
"    </a>",
"    ). In addition, FluNet, a database for global influenza virus surveillance, is available via the WHO web site (",
"    <a class=\"external\" href=\"file://www.who.int/influenza/gisrs_laboratory/flunet/en/\">",
"     file://www.who.int/influenza/gisrs_laboratory/flunet/en/",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       \"Patient information: Flu (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1200926664\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza occurs in distinct outbreaks of varying extent every year. This epidemiologic pattern reflects the changing nature of the antigenic properties of influenza viruses, and their subsequent spread depends upon multiple factors, including transmissibility of the virus and the susceptibility of the population. Influenza A viruses, in particular, have a remarkable ability to undergo periodic changes in their antigenic envelope glycoproteins, the hemagglutinin and the neuraminidase. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major changes in the hemagglutinin and neuraminidase glycoproteins are referred to as antigenic shifts, and minor changes are called antigenic drifts. Antigenic shifts are associated with epidemics and pandemics of influenza A, whereas antigenic drifts are associated with more localized outbreaks of varying extent. (See",
"      <a class=\"local\" href=\"#H1200927955\">",
"       'Definition of antigenic shifts and drifts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Antigenic shifts'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Antigenic drifts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among influenza A viruses that infect humans, three major subtypes of hemagglutinins (H1, H2, and H3) and two subtypes of neuraminidases (N1 and N2) have been described. Influenza B viruses have a lesser propensity for antigenic changes, and only antigenic drifts in the hemagglutinin have been described. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Influenza viruses have a segmented genome that can result in high rates of reassortment among viruses coinfecting the same cell. Reassortment between animal and human viruses may result in the emergence of pandemic strains. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Antigenic shifts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The extremely severe pandemic of 1918 and 1919 was associated with the emergence of antigenic shifts in both the hemagglutinin (H1) and the neuraminidase (N1) of influenza A. Subsequent less severe pandemics occurred in 1957, 1968, 1977, and 2009 (",
"      <a class=\"graphic graphic_table graphicRef52181 \" href=\"UTD.htm?15/58/16300\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pandemic of 1918'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Other pandemics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outbreaks of influenza occur almost exclusively during the winter months in the northern and southern hemispheres, but may occur throughout the year in the tropics. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Seasonality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of high attack rates, the morbidity caused by influenza in the general population is substantial. Increased rates of morbidity and mortality occur at the extremes of age and with underlying comorbidities. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Morbidity and mortality in adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although death rates from influenza are usually disproportionately higher among elderly individuals and infants during influenza epidemics, a shift in the age distribution is seen during pandemics. During pandemics, higher rates of mortality occur not only at the extremes of age, but also in young adults (",
"      <a class=\"graphic graphic_figure graphicRef75017 \" href=\"UTD.htm?34/44/35534\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Mortality during influenza pandemics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dolin R. Influenza. In: Harrison's Principles of Internal Medicine, 17, Braunwald E, Fauci AS, Kasper DL, et al (Eds), McGraw Hill, New York 2008. p.1127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/2\">",
"      Webster RG, Wright SM, Castrucci MR, et al. Influenza--a model of an emerging virus disease. Intervirology 1993; 35:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/3\">",
"      Ellis JS, Alvarez-Aguero A, Gregory V, et al. Influenza AH1N2 viruses, United Kingdom, 2001-02 influenza season. Emerg Infect Dis 2003; 9:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/4\">",
"      Paget WJ, Meerhoff TJ, Goddard NL, EISS. Mild to moderate influenza activity in Europe and the detection of novel A(H1N2) and B viruses during the winter of 2001-02. Euro Surveill 2002; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/5\">",
"      Xu X, Smith CB, Mungall BA, et al. Intercontinental circulation of human influenza A(H1N2) reassortant viruses during the 2001-2002 influenza season. J Infect Dis 2002; 186:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/6\">",
"      Morens DM, Taubenberger JK, Folkers GK, Fauci AS. Pandemic influenza's 500th anniversary. Clin Infect Dis 2010; 51:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/7\">",
"      Taubenberger JK, Reid AH, Krafft AE, et al. Initial genetic characterization of the 1918 \"Spanish\" influenza virus. Science 1997; 275:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/8\">",
"      Masurel N, Marine WM. Recycling of Asian and Hong Kong influenza A virus hemagglutinins in man. Am J Epidemiol 1973; 97:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/9\">",
"      Kendal AP, Schieble J, Cooney MK, et al. Co-circulation of two influenza A (H3N2) antigenic variants detected by virus surveillance in individual communities. Am J Epidemiol 1978; 108:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Update: Influenza A (H3N2)v transmission and guidelines - five states, 2011. MMWR Morb Mortal Wkly Rep 2012; 60:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Outbreak of influenza A (H3N2) virus among persons and swine at a county fair--Indiana, July 2012. MMWR Morb Mortal Wkly Rep 2012; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC reports cases 18-29 of H3N2v virus infection; continues to recommend interim precautions when interacting with pigs. file://www.cdc.gov/flu/spotlights/h3n2v_us_cases.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. First H3N2 variant virus infection reported for 2012. file://www.cdc.gov/flu/spotlights/h3n2v-variant-utah.htm (Accessed on August 10, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Information on influenza A (H3N2) variant viruses (&ldquo;H3N2v&rdquo;). file://www.cdc.gov/flu/swineflu/influenza-variant-viruses-h3n2v.htm#table (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Interim information for clinicians about human infections with H3N2v virus. file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Evaluation of rapid influenza diagnostic tests for influenza A (H3N2)v virus and updated case count--United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:619.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Case count: detected U.S. human infections with H3N2v by state since August 2011 file://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm (Accessed on September 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Influenza A (H3N2) variant virus-related hospitalizations: Ohio, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/19\">",
"      Skowronski DM, Janjua NZ, De Serres G, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis 2012; 206:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/20\">",
"      Webster RG, Kendal AP, Gerhard W. Analysis of antigenic drift in recently isolated influenza A (H1N1) viruses using monoclonal antibody preparations. Virology 1979; 96:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/21\">",
"      Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 \"Spanish\" influenza pandemic. Bull Hist Med 2002; 76:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/22\">",
"      Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st century. J Infect Dis 2007; 195:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/23\">",
"      Kobasa D, Takada A, Shinya K, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 2004; 431:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/24\">",
"      Hoft DF, Belshe RB. The genetic archaeology of influenza. N Engl J Med 2004; 351:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/25\">",
"      Tumpey TM, Basler CF, Aguilar PV, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 2005; 310:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/26\">",
"      Taubenberger JK, Reid AH, Lourens RM, et al. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/27\">",
"      Bresee J, Hayden FG. Epidemic influenza--responding to the expected but unpredictable. N Engl J Med 2013; 368:589.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Seasonal Influenza (Flu) - Flu View. file://www.cdc.gov/flu/weekly/ (Accessed on April 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/29\">",
"      Su WJ, Shao PL, Liu MT, et al. Low seroprotection against preseasonal influenza local strains in children might predict the upcoming epidemic influenza strains. Clin Infect Dis 2010; 51:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/30\">",
"      Moura FE. Influenza in the tropics. Curr Opin Infect Dis 2010; 23:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/31\">",
"      Azziz Baumgartner E, Dao CN, Nasreen S, et al. Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis 2012; 206:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/32\">",
"      Brownstein JS, Wolfe CJ, Mandl KD. Empirical evidence for the effect of airline travel on inter-regional influenza spread in the United States. PLoS Med 2006; 3:e401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/33\">",
"      Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978; 298:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/34\">",
"      Monto AS, Kioumehr F. The Tecumseh Study of Respiratory Illness. IX. Occurence of influenza in the community, 1966--1971. Am J Epidemiol 1975; 102:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/35\">",
"      Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/36\">",
"      Dao CN, Kamimoto L, Nowell M, et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. J Infect Dis 2010; 202:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/37\">",
"      Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/38\">",
"      Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/39\">",
"      Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/40\">",
"      Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis 2006; 42:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/41\">",
"      Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/42\">",
"      Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/43\">",
"      Cohen C, Simonsen L, Kang JW, et al. Elevated influenza-related excess mortality in South African elderly individuals, 1998-2005. Clin Infect Dis 2010; 51:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/44\">",
"      van Asten L, van den Wijngaard C, van Pelt W, et al. Mortality attributable to 9 common infections: significant effect of influenza A, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis 2012; 206:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/45\">",
"      Wu P, Goldstein E, Ho LM, et al. Excess mortality associated with influenza A and B virus in Hong Kong, 1998-2009. J Infect Dis 2012; 206:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/46\">",
"      Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999; 281:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/47\">",
"      Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/48\">",
"      Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/49\">",
"      Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/50\">",
"      Viboud C, Grais RF, Lafont BA, et al. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect Dis 2005; 192:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/51\">",
"      Brundage JF, Shanks GD. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis 2008; 14:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15272/abstract/52\">",
"      Sheng ZM, Chertow DS, Ambroggio X, et al. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci U S A 2011; 108:16416.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7006 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15272=[""].join("\n");
var outline_f14_58_15272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1200926664\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1200927955\">",
"      DEFINITION OF ANTIGENIC SHIFTS AND DRIFTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIGENIC SHIFTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pandemic of 1918",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other pandemics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104949276\">",
"      H3N2 variant influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTIGENIC DRIFTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHARACTERISTICS OF INFLUENZA OUTBREAKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Seasonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Time course of an outbreak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Factors determining the severity of an outbreak",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTIBODY RESPONSE TO THE 1918 PANDEMIC STRAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MORBIDITY AND MORTALITY IN ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mortality during influenza pandemics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1120576803\">",
"      RISK FACTORS FOR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1200929549\">",
"      INFLUENZA ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1200926664\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7006\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7006|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/44/35534\" title=\"figure 1\">",
"      Pandemic influenza mortality 1918",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7006|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/58/16300\" title=\"table 1\">",
"      Antigenic subtypes of influenza",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27946?source=related_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_58_15273="Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid";
var content_f14_58_15273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15273/contributors\">",
"     Kristin M Leiferman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15273/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/58/15273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/58/15273/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/58/15273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H589229\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous pemphigoid and mucous membrane pemphigoid (MMP) are uncommon autoimmune subepithelial blistering diseases that most frequently arise in older adults and are characterized by the presence of cutaneous bullae and erosive mucosal lesions. Significant progress has been made in understanding the pathogenesis of these diseases. Multiple events, including the binding of immunoglobulins to basement membrane zone components, the subsequent activation of complement, and the migration of inflammatory cells into the subepithelial tissue, likely contribute to the clinical manifestations of bullous pemphigoid and MMP.",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis of bullous pemphigoid and MMP will be reviewed here. The clinical features, diagnosis, and treatment of these disorders and greater detail on the ocular form of MMP (ocular cicatricial pemphigoid) are available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3770?source=see_link\">",
"     \"Management and prognosis of bullous pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39544?source=see_link\">",
"     \"Management of mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link\">",
"     \"Ocular cicatricial pemphigoid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589237\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigoid disorders, which include bullous pemphigoid, MMP, anti-laminin 332 pemphigoid (also known as anti-epiligrin cicatricial pemphigoid), pemphigoid gestationis, Brunsting-Perry pemphigoid, and anti-laminin &gamma;1 (anti-p200) pemphigoid are characterized clinically by the presence of inflammatory, blistering,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    erosive mucocutaneous lesions, and histologically by subepithelial cleavage and IgG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complement deposits at the epidermal basement membrane zone (",
"    <a class=\"graphic graphic_picture graphicRef66267 graphicRef86373 \" href=\"UTD.htm?26/44/27338\">",
"     picture 1A-B",
"    </a>",
"    ). The location of blistering and immunoglobulin deposition distinguishes pemphigoid disorders from pemphigus. In pemphigus, blister formation and antibody deposition occur within the",
"    <span class=\"nowrap\">",
"     epidermis/epithelium",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef60749 graphicRef82837 \" href=\"UTD.htm?23/54/24426\">",
"     picture 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMP is not a single disease, rather it represents a group of heterogeneous, chronic subepithelial blistering diseases that primarily affect mucosal surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/1\">",
"     1",
"    </a>",
"    ]. Historically, because of the scarring sequelae that may develop clinically, the term",
"    <strong>",
"     cicatricial pemphigoid",
"    </strong>",
"    was ascribed to diseases now categorized as MMP.",
"   </p>",
"   <p>",
"    Some authors also consider mucosal-predominant forms of linear IgA bullous dermatosis and epidermolysis bullosa acquisita as forms of MMP [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/1\">",
"     1",
"    </a>",
"    ]. However, our preference is to consider these diagnoses as distinct disease entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link\">",
"     \"Linear IgA bullous dermatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"     \"Epidermolysis bullosa acquisita\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A table summarizing the major forms of pemphigoid and non-pemphigoid autoimmune blistering disorders is provided (",
"    <a class=\"graphic graphic_table graphicRef76641 \" href=\"UTD.htm?11/13/11484\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589244\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the data on the incidence of bullous pemphigoid are derived from European reports, in which studies documenting incidence rates of 4 to 22 cases per million individuals per year support the designation of bullous pemphigoid as an uncommon disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The results of a French retrospective study suggest that the incidence of bullous pemphigoid may be increasing. The annual incidence rate for bullous pemphigoid between 2000 and 2005 (22 cases per million inhabitants per year) was three times greater than the estimated incidence rate between 1986 and 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bullous pemphigoid is considered the most common autoimmune blistering disorder in Europe. However, in locations such as Thailand and Malaysia, pemphigus may be more common [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bullous pemphigoid is primarily a disease of the elderly; the vast majority of cases occur in individuals over the age of 60 years and occurrence in children is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In a retrospective study of 869 patients with bullous pemphigoid in the United Kingdom, the median patient age at the time of presentation was 80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased risk of bullous pemphigoid with advancing age was illustrated in two European prospective studies that were based upon data collected in 2001 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. In a German study, the estimated incidence rate in the general population was 13 cases per million individuals per year, but rose to 189 cases per million individuals per year among those over the age of 80 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/10\">",
"     10",
"    </a>",
"    ]. Similarly, a sharp rise in incidence was evident in a Swiss study in which the incidence of bullous pemphigoid increased from 12 cases per million individuals per year in the general population to 163 cases per million individuals among those over the age of 90 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MMP is less common than bullous pemphigoid; in the German study cited above, the estimated incidence rate in the general population was two cases per million inhabitants per year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/10\">",
"     10",
"    </a>",
"    ]. Like bullous pemphigoid, MMP is most likely to occur in older individuals and is rare in children [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. Patients with MMP most frequently are within the age range of 60 to 80 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gender also may play a role in risk for bullous pemphigoid and MMP. Multiple studies have reported at least a slight female predominance in these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/2,5,13\">",
"     2,5,13",
"    </a>",
"    ]. The reasons for this observation are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589251\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms that lead to bullous pemphigoid and MMP are not fully understood, but most likely involve autoantibody-mediated damage to epithelial basement membrane zone, a complex structure that mediates adhesion, permeability, and cellular organization and differentiation (",
"    <a class=\"graphic graphic_figure graphicRef67891 graphicRef86896 \" href=\"UTD.htm?15/17/15642\">",
"     figure 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The binding of antibodies to antigens within the epithelial basement membrane zone stimulates a destructive inflammatory cascade that results in separation of the epidermis from the dermis in skin and epithelium from subepithelial tissue in mucous membranes with the formation of characteristic cutaneous and mucosal lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783753\">",
"    <span class=\"h2\">",
"     Antigenic targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to several antigens have been identified as potential contributors to bullous pemphigoid and MMP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589258\">",
"    <span class=\"h3\">",
"     Bullous pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In bullous pemphigoid, autoantibodies against two principal hemidesmosomal proteins are strongly linked to clinical disease: bullous pemphigoid antigen 180 (BP 180), a 180 kilodalton protein also known as bullous pemphigoid antigen 2 (BPAg2) and type XVII collagen, and bullous pemphigoid antigen 230 (BP 230), a 230 kilodalton protein also referred to as bullous pemphigoid antigen 1 (BPAg1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589265\">",
"    <span class=\"h4\">",
"     BP180",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against BP180, a transmembrane protein that extends from the hemidesmosome dense plaque in basal keratinocytes into the lamina densa of the basement membrane zone (",
"    <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"     figure 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/16\">",
"     16",
"    </a>",
"    ], are present in the vast majority of patients with bullous pemphigoid. Antibodies against the noncollagenous extracellular domain of BP180 known as NC16A (the primary site for antibody binding in bullous pemphigoid) are detectable via enzyme-linked immunosorbent assay (ELISA) in 80 to 90 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/15,17-22\">",
"     15,17-22",
"    </a>",
"    ]. The production of antibodies to other epitopes of BP180 also occurs in bullous pemphigoid, and may have clinical significance. As an example, antibodies directed against epitopes in the C-terminal end of BP180 have been associated with the presence of mucosal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important role for antibodies against BP180 in bullous pemphigoid is supported by animal models in which the transfer of BP180 IgG antibodies resulted in the development of skin lesions that resembled bullous pemphigoid (see",
"    <a class=\"local\" href=\"#H864458\">",
"     'Animal models'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Additional support is derived from the observation that serum levels of antibodies against the NC16A epitope correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominant subclass of antibodies that react with the basement membrane zone in bullous pemphigoid is IgG4 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. IgG4 antibodies also are present in the prodromal phase of bullous pemphigoid that often precedes cutaneous blistering [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/31\">",
"     31",
"    </a>",
"    ]. IgG1 and IgG2 antibodies may be present in bullous pemphigoid, but are less frequently detected than IgG4 antibodies. IgG3 antibodies are usually absent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although BP180 antibodies of the IgG class are most frequently detected in bullous pemphigoid, IgA and IgE BP180 antibodies also may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/14,30-33\">",
"     14,30-33",
"    </a>",
"    ]. The relevance of IgA antibodies in bullous pemphigoid remains uncertain. Cases in which a predominance of IgA basement membrane zone localization is detected actually may represent linear IgA bullous dermatosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link&amp;anchor=H827478#H827478\">",
"     \"Linear IgA bullous dermatosis\", section on 'Pathogenesis'",
"    </a>",
"    ). There is some evidence to support a pathogenic role for IgE basement membrane zone antibodies, including a small retrospective study that identified an association with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/28,34-37\">",
"     28,34-37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Of note, antibodies against BP180 also occur in other subepidermal autoimmune blistering diseases. IgG BP180 antibodies may be detected in patients with MMP and pemphigoid gestationis. (See",
"    <a class=\"local\" href=\"#H589279\">",
"     'Mucous membrane pemphigoid'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link&amp;anchor=H2#H2\">",
"     \"Dermatoses of pregnancy\", section on 'Pemphigoid gestationis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589272\">",
"    <span class=\"h4\">",
"     BP230",
"    </span>",
"    &nbsp;&mdash;&nbsp;BP230 is an intracellular hemidesmosomal protein in the plakin family that is found in basal keratinocytes (",
"    <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"     figure 1A",
"    </a>",
"    ). In conjunction with plectin, another hemidesmosomal plakin, BP230 links keratin intermediate filaments to the hemidesmosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/16\">",
"     16",
"    </a>",
"    ]. Antibodies to BP230 are detected in approximately 60 to 70 percent of patients with bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/14,33\">",
"     14,33",
"    </a>",
"    ]. The primary site of antibody binding on BP230 is at the globular C-terminal domain [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/14,33\">",
"     14,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether BP230 antibodies have a pathogenic role in bullous pemphigoid or whether they occur as a secondary event related to keratinocyte injury [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/14\">",
"     14",
"    </a>",
"    ]. Serum levels of antibodies against BP230 do not reveal consistent correlation with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. In addition, the intracellular location of BP230 likely limits access of BP230 antibodies to the antigen. Nevertheless, in our experience, there is a subset of pemphigoid patients with increased BP230 antibody levels and normal BP180 antibody levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589279\">",
"    <span class=\"h3\">",
"     Mucous membrane pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies against several basement membrane zone antigens have been detected in patients with MMP, some of which correlate with distinctive clinical features. The major basement membrane zone proteins targeted in MMP include (",
"    <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"     figure 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/1,41-43\">",
"     1,41-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BP180 (C terminal domain)",
"     </li>",
"     <li>",
"      BP230",
"     </li>",
"     <li>",
"      Laminin 332 (also known as laminin 5 or epiligrin)",
"     </li>",
"     <li>",
"      &alpha;6&beta;4 integrin",
"     </li>",
"     <li>",
"      Type VII collagen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The precise location of antibody binding can have clinical relevance in MMP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Scarring",
"      </strong>",
"      &ndash; The site of antibody binding may account for the frequent development of scarring in MMP lesions, a feature that typically is not observed in bullous pemphigoid. In contrast to bullous pemphigoid, in which antibody binding occurs to epitopes located in hemidesmosomes and the upper lamina lucida, antibody-binding in MMP is primarily located in the lower lamina lucida and lamina densa [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/44\">",
"       44",
"      </a>",
"      ]. This deeper location of antibody binding may increase the risk for scarring. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290512#H53290512\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Sites of disease",
"      </strong>",
"      &ndash; Ocular involvement is associated with antibodies to the &beta;4 integrin subunit of &alpha;6&beta;4 integrin, whereas antibodies to the &alpha;6 subunit have been linked to oral disease [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H2913490#H2913490\">",
"       \"Ocular cicatricial pemphigoid\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Risk for associated malignancy",
"      </strong>",
"      &ndash; Antibodies to laminin 332, which are estimated to occur in approximately 25 percent of patients with MMP, are associated with an increased risk for internal malignancy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H3867571#H3867571\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Malignancy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the specific epitope or epitopes targeted, the number and type of autoantibodies that bind to the basement membrane zone may be clinically relevant in MMP. Autoantibodies to multiple basement membrane antigens or multiple epitopes on BP180, as well as the combined presence of IgG and IgA basement membrane zone antibodies have been associated with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/45,48\">",
"     45,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783729\">",
"    <span class=\"h3\">",
"     Anti-laminin &gamma;1 pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laminins are heterotrimers composed of one of five alpha chains, one of four &beta; chains, and one of three &gamma; chains. The laminins are named based on their polypeptide chain assortment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/49\">",
"     49",
"    </a>",
"    ]; for example, laminin 311 is composed of the laminin &alpha;3, &beta;1, and &gamma;1 chains. At least 15 laminins are described of which at least three are important extracellular matrix glycoproteins in the basement membrane zone, laminin 311 (laminin 6), laminin 332, and laminin 551 (formerly known as laminin 10).",
"   </p>",
"   <p>",
"    Anti-laminin &gamma;1 pemphigoid (also known as anti-p200 pemphigoid) is a more recently described type of pemphigoid that clinically resembles bullous pemphigoid. This type of pemphigoid is distinguished by the presence of antibodies to a 200 kilodalton protein which corresponds with the &gamma;1 subunit of laminin 311 in the epithelial basement membrane zone (",
"    <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"     figure 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H12467889#H12467889\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Laminin &gamma;1 pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590340\">",
"    <span class=\"h2\">",
"     Role of pathogenic antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody-mediated activation of the complement cascade by antibodies bound to specific antigens in the basement membrane zone has been proposed as a principal mechanism for lesion formation in bullous pemphigoid and MMP [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/14,15,53,54\">",
"     14,15,53,54",
"    </a>",
"    ]. The activation of complement may stimulate the local recruitment of inflammatory cells that release proinflammatory mediators as well as proteases that directly damage the basement membrane zone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In bullous pemphigoid, the presence of mast cells and eosinophils may contribute significantly to clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/57-60\">",
"     57-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acceptance of basement membrane zone antibodies as the exclusive cause of bullous pemphigoid is complicated by the observation that some patients with detectable circulating basement membrane zone antibodies lack clinical signs of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. In one study, BP180, BP230, or both antibody levels determined by ELISA were increased in 5 out of 15 elderly patients with pruritus and no other clinical or laboratory evidence of bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/63\">",
"     63",
"    </a>",
"    ]. It is unclear whether these results represented the identification of a prodromal phase of bullous pemphigoid or coincidental findings unrelated to the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H864458\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies utilizing animal models have contributed significantly to the understanding of the pathogenesis of bullous pemphigoid and MMP. The pathogenic role of BP180 antibodies is supported by animal models of bullous pemphigoid that indicate that IgG antibodies to a basement membrane zone antigen analogous to BP180 in the animal species are capable of activating complement and inducing features consistent with bullous pemphigoid, including blister development and mast cell degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Moreover, passive transfer experiments in which human BP180 antibodies are delivered to mice humanized with BP180 antigen demonstrate basement membrane separation that is dependent upon complement, neutrophils, and mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the observations that animal models of bullous pemphigoid primarily demonstrate neutrophil infiltration (similar to that seen in linear IgA disease), rather than eosinophil infiltration and eosinophil degranulation, which are characteristic of human bullous pemphigoid, indicate that the understanding of the pathogenesis of bullous pemphigoid remains incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/57,59,60\">",
"     57,59,60",
"    </a>",
"    ]. It is likely that additional factors not present in the passive transfer models are responsible for eosinophil infiltration in humans. A murine model of bullous pemphigoid with IgE antibodies recapitulates the inflammatory infiltrate in pemphigoid more closely [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/65\">",
"     65",
"    </a>",
"    ]. Additional study is necessary to determine whether IgE plays a pathogenic role in human disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H589286\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although further study is necessary to elucidate the pathways that lead to bullous pemphigoid and MMP, genetic factors, environmental exposures, and the phenomenon of epitope spreading are considered potential contributory factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590409\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain human leukocyte antigen (HLA) alleles may play a role in bullous pemphigoid and MMP. In MMP, increased prevalence of the HLA-DQB1*0301 allele has been reported in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/66-69\">",
"     66-69",
"    </a>",
"    ], and the same allele was associated with bullous pemphigoid in a small series of patients in the United States and Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/67,70\">",
"     67,70",
"    </a>",
"    ]. However, these findings may not be applicable to all populations, as this allele was not associated with bullous pemphigoid in two studies performed in Japanese and Chinese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. In the Japanese study, several other potential susceptibility alleles were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proposed mechanism through which certain HLA alleles might contribute to risk for bullous pemphigoid or MMP involves the facilitation of antigen presentation of basement membrane zone antigens to T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/54\">",
"     54",
"    </a>",
"    ]. Further studies are necessary to explore the role of genetic factors in the development of these diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590419\">",
"    <span class=\"h3\">",
"     Infections and drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune reactions triggered by exposure to infections or drugs may play a role in bullous pemphigoid and MMP. In theory, these disorders could occur as a result of cross-reactivity of antibodies that target infectious agents or drugs with antigens in the basement membrane zone. Although no specific infectious disorder has been definitively associated with pemphigoid, in a small case-control study, antibodies against hepatitis B, hepatitis C,",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    ,",
"    <em>",
"     Toxoplasma gondii",
"    </em>",
"    , and cytomegalovirus were more prevalent among patients with bullous disease (pemphigus or bullous pemphigoid) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug-induced forms of bullous pemphigoid and MMP have been reported in association with multiple medications. A table listing reported agents is provided (",
"    <a class=\"graphic graphic_table graphicRef56085 \" href=\"UTD.htm?0/48/781\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590428\">",
"    <span class=\"h3\">",
"     Epitope spreading",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term epitope spreading has been used to describe the induction of an autoimmune response against normally tolerated host antigens and epitopes as a consequence of the exposure of these antigens and epitopes during immune-mediated tissue inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/73\">",
"     73",
"    </a>",
"    ]. Epitope spreading has been proposed as an explanation for cases in which pemphigoid occurred in the setting of other diseases. As examples, ocular cicatricial pemphigoid has developed following conjunctival inflammation due to Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/74\">",
"     74",
"    </a>",
"    ] and, in lichen planus pemphigoides (a variant of bullous pemphigoid), the onset of bullous lesions occurs weeks to months after the development of lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H2913490#H2913490\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290498#H53290498\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spreading of the immune response against epidermal basement membrane zone antigens to or from similarly structured proteins in other body sites also may occur. The development of bullous pemphigoid in several renal transplant patients has been attributed to the concept that autoantibody formation against the glomerular basement membrane zone may have contributed to the development of bullous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/76\">",
"     76",
"    </a>",
"    ]. This phenomenon also has been proposed as a contributor to the observed link between bullous pemphigoid and certain neurologic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?14/58/15273/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H3867564#H3867564\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Neurologic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/11/3250?source=see_link\">",
"       \"Patient information: Bullous pemphigoid (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783847\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bullous pemphigoid and mucous membrane pemphigoid (MMP) are uncommon autoimmune subepithelial bullous disorders that present with blistering",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      erosive cutaneous and mucosal lesions (",
"      <a class=\"graphic graphic_table graphicRef76641 \" href=\"UTD.htm?11/13/11484\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H589237\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bullous pemphigoid and MMP primarily occur in the older population. Most patients affected by these disorders are over the age of 60 years. Bullous pemphigoid and MMP are rare in children. (See",
"      <a class=\"local\" href=\"#H589244\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of bullous pemphigoid and MMP likely result from the destructive and inflammatory consequences related to antibody binding in the epithelial basement membrane zone in skin and mucous membranes. (See",
"      <a class=\"local\" href=\"#H589251\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bullous pemphigoid antigen 180 (BP180) and bullous pemphigoid antigen 230 (BP230) are two principal basement membrane zone antigens targeted by antibodies in patients with bullous pemphigoid (",
"      <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"       figure 1A",
"      </a>",
"      ). Although antibodies formed against BP180 are likely pathogenic, a pathogenic role for BP230 antibodies is uncertain. (See",
"      <a class=\"local\" href=\"#H589258\">",
"       'Bullous pemphigoid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple antigenic targets have been linked to MMP. Of note, antibodies against laminin 332 (also known as laminin 5 or epiligrin) are associated with an increased risk for malignancy, and antibodies against the &beta;4 subunit of &alpha;6&beta;4 integrin are linked to ocular disease (ocular cicatricial pemphigoid). (See",
"      <a class=\"local\" href=\"#H589279\">",
"       'Mucous membrane pemphigoid'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H3867571#H3867571\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Malignancy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H2913490#H2913490\">",
"       \"Ocular cicatricial pemphigoid\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic factors, environmental exposures, and the phenomenon of epitope spreading may impact the development of bullous pemphigoid and MMP. Additional studies are necessary to explore the relationships of these factors to disease expression. (See",
"      <a class=\"local\" href=\"#H589286\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/1\">",
"      Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/2\">",
"      Marazza G, Pham HC, Sch&auml;rer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/3\">",
"      Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/4\">",
"      Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/5\">",
"      Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol 2011; 29:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/6\">",
"      Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol 1992; 31:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/7\">",
"      Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010; 29:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/8\">",
"      Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/9\">",
"      Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ 2008; 337:a180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/10\">",
"      Bertram F, Br&ouml;cker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/11\">",
"      Kharfi M, Khaled A, Anane R, et al. Early onset childhood cicatricial pemphigoid: a case report and review of the literature. Pediatr Dermatol 2010; 27:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/12\">",
"      Knudson RM, Kalaaji AN, Bruce AJ. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010; 23:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/13\">",
"      Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/14\">",
"      Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity 2012; 45:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/15\">",
"      Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev 2011; 10:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/16\">",
"      Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet 2002; 3:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/17\">",
"      Mariotti F, Grosso F, Terracina M, et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 2004; 151:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/18\">",
"      Sakuma-Oyama Y, Powell AM, Oyama N, et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol 2004; 151:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/19\">",
"      Barnadas MA, Rubiales MV, Gonz&aacute;lez MJ, et al. Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis. Int J Dermatol 2008; 47:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/20\">",
"      Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/21\">",
"      Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/22\">",
"      Ishiura N, Fujimoto M, Watanabe R, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2008; 49:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/23\">",
"      Hofmann S, Thoma-Uszynski S, Hunziker T, et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002; 119:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/24\">",
"      Di Zenzo G, Grosso F, Terracina M, et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 2004; 122:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/25\">",
"      Li Q, Ujiie H, Shibaki A, et al. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model. J Immunol 2010; 185:7746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/26\">",
"      Ujiie H, Shibaki A, Nishie W, et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol 2010; 184:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/27\">",
"      Heimbach L, Li N, Diaz A, Liu Z. Experimental animal models of bullous pemphigoid. G Ital Dermatol Venereol 2009; 144:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/28\">",
"      D&ouml;pp R, Schmidt E, Chimanovitch I, et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/29\">",
"      Schmidt E, Obe K, Br&ouml;cker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/30\">",
"      Shirakata Y, Shiraishi S, Sayama K, Miki Y. Subclass characteristics of IgG autoantibodies in bullous pemphigoid and pemphigus. J Dermatol 1990; 17:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/31\">",
"      Lamb PM, Patton T, Deng JS. The predominance of IgG4 in prodromal bullous pemphigoid. Int J Dermatol 2008; 47:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/32\">",
"      Kromminga A, Scheckenbach C, Georgi M, et al. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. J Autoimmun 2000; 15:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/33\">",
"      Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/34\">",
"      Woodley DT. The role of IgE anti-basement membrane zone autoantibodies in bullous pemphigoid. Arch Dermatol 2007; 143:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/35\">",
"      Fairley JA, Burnett CT, Fu CL, et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007; 127:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/36\">",
"      Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/37\">",
"      Arbesman CE, Wypych JI, Reisman RE, Beutner EH. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974; 110:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/38\">",
"      Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/39\">",
"      Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/40\">",
"      Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/41\">",
"      Rashid KA, G&uuml;rcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006; 126:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/42\">",
"      Chan LS, Majmudar AA, Tran HH, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997; 108:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/43\">",
"      Lazarova Z, Yee C, Lazar J, Yancey KB. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol 2001; 101:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/44\">",
"      B&eacute;dane C, McMillan JR, Balding SD, et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/45\">",
"      Oyama N, Setterfield JF, Powell AM, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol 2006; 154:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/46\">",
"      Zakka LR, Reche P, Ahmed AR. Role of MHC Class II genes in the pathogenesis of pemphigoid. Autoimmun Rev 2011; 11:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/47\">",
"      Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/48\">",
"      Setterfield J, Shirlaw PJ, Bhogal BS, et al. Cicatricial pemphigoid: serial titres of circulating IgG and IgA antibasement membrane antibodies correlate with disease activity. Br J Dermatol 1999; 140:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/49\">",
"      Aumailley M, Bruckner-Tuderman L, Carter WG, et al. A simplified laminin nomenclature. Matrix Biol 2005; 24:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/50\">",
"      Dainichi T, Kurono S, Ohyama B, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009; 106:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/51\">",
"      Groth S, Recke A, Vafia K, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011; 164:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/52\">",
"      Dainichi T, Koga H, Tsuji T, et al. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid. J Dermatol 2010; 37:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/53\">",
"      Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995; 95:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/54\">",
"      Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 2000; 284:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/55\">",
"      Verraes S, Hornebeck W, Polette M, et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 2001; 117:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/56\">",
"      St&aring;hle-B&auml;ckdahl M, Inoue M, Guidice GJ, Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 1994; 93:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/57\">",
"      Dvorak AM, Mihm MC Jr, Osage JE, et al. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol 1982; 78:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/58\">",
"      Wintroub BU, Mihm MC Jr, Goetzl EJ, et al. Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. N Engl J Med 1978; 298:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/59\">",
"      Borrego L, Maynard B, Peterson EA, et al. Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins. Am J Pathol 1996; 148:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/60\">",
"      Goldstein SM, Wasserman SI, Wintroub BU. Mast cell and eosinophil mediated damage in bullous pemphigoid. Immunol Ser 1989; 46:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/61\">",
"      Wieland CN, Comfere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/62\">",
"      Aoyama Y, Asai K, Hioki K, et al. Herpes gestationis in a mother and newborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain. Arch Dermatol 2007; 143:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/63\">",
"      Feliciani C, Caldarola G, Kneisel A, et al. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br J Dermatol 2009; 161:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/64\">",
"      Liu Z, Sui W, Zhao M, et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008; 31:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/65\">",
"      Zone JJ, Taylor T, Hull C, et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007; 127:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/66\">",
"      Chan LS, Hammerberg C, Cooper KD. Significantly increased occurrence of HLA-DQB1*0301 allele in patients with ocular cicatricial pemphigoid. J Invest Dermatol 1997; 108:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/67\">",
"      Delgado JC, Turbay D, Yunis EJ, et al. A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci U S A 1996; 93:8569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/68\">",
"      Setterfield J, Theron J, Vaughan RW, et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001; 145:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/69\">",
"      Yunis JJ, Mobini N, Yunis EJ, et al. Common major histocompatibility complex class II markers in clinical variants of cicatricial pemphigoid. Proc Natl Acad Sci U S A 1994; 91:7747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/70\">",
"      B&uuml;dinger L, Borradori L, Yee C, et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 1998; 102:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/71\">",
"      Okazaki A, Miyagawa S, Yamashina Y, et al. Polymorphisms of HLA-DR and -DQ genes in Japanese patients with bullous pemphigoid. J Dermatol 2000; 27:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/72\">",
"      Gao XH, Winsey S, Li G, et al. HLA-DR and DQ polymorphisms in bullous pemphigoid from northern China. Clin Exp Dermatol 2002; 27:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/73\">",
"      Di Zenzo G, Thoma-Uszynski S, Calabresi V, et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 2011; 131:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/74\">",
"      Chan LS, Soong HK, Foster CS, et al. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA 1991; 266:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/75\">",
"      Mignogna MD, Fortuna G, Leuci S, et al. Lichen planus pemphigoides, a possible example of epitope spreading. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/76\">",
"      Devaux S, Michot C, Mourad G, et al. Chronic renal graft rejection-associated bullous pemphigoid: A cross-reactive immune response? Acta Derm Venereol 2011; 91:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/77\">",
"      Bouras C, Riederer BM, K&ouml;vari E, et al. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Brain Res Rev 2005; 48:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/78\">",
"      Laffitte E, Burkhard PR, Fontao L, et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol 2005; 152:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/79\">",
"      Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 2011; 57:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/58/15273/abstract/80\">",
"      Li L, Chen J, Wang B, et al. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160:1343.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16864 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15273=[""].join("\n");
var outline_f14_58_15273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H783847\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589229\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589237\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589244\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H589251\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H783753\">",
"      Antigenic targets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589258\">",
"      - Bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H589265\">",
"      BP180",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H589272\">",
"      BP230",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H589279\">",
"      - Mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H783729\">",
"      - Anti-laminin &gamma;1 pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590340\">",
"      Role of pathogenic antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H864458\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H589286\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H590409\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H590419\">",
"      - Infections and drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H590428\">",
"      - Epitope spreading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H783847\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16864|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/63/4086\" title=\"figure 1A\">",
"      Epidermal basement membrane zone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/16/5383\" title=\"figure 1B\">",
"      Epidermal basement membrane zone - EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16864|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/15/44279\" title=\"picture 1A\">",
"      Bullous pemphigoid pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/25/31126\" title=\"picture 1B\">",
"      Bullous pemphigoid direct immunofluorescence 200X",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/25/33173\" title=\"picture 2A\">",
"      Pemphigus vulgaris biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/58/10152\" title=\"picture 2B\">",
"      Pemphigus vulgaris DIF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16864|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/13/11484\" title=\"table 1\">",
"      Autoimmune blistering diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/48/781\" title=\"table 2\">",
"      Drug causes of pemphigoid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=related_link\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3770?source=related_link\">",
"      Management and prognosis of bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39544?source=related_link\">",
"      Management of mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=related_link\">",
"      Ocular cicatricial pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/11/3250?source=related_link\">",
"      Patient information: Bullous pemphigoid (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_58_15274="Severe cirrhosis iron overload";
var content_f14_58_15274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micronodular cirrhosis in sideroblastic anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 531px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver sections from a 45-year-old man with pyridoxine-responsive sideroblastic anemia and micronodular cirrhosis resulting from iron overload. Top panel: hematoxylin and eosin stain. Bottom panel: Prussian blue (iron) stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sylvia Bottomley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15274=[""].join("\n");
var outline_f14_58_15274=null;
var title_f14_58_15275="Components of a first trimester ultrasound examination";
var content_f14_58_15275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components of a first trimester ultrasound examination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Gestational sac (location, diameter if no embryo identified)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence or absence of a yolk sac (diameter)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence or absence of an embryo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence or absence of cardiac activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crown rump length, if technically possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of embryos",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amnionicity and chorionicity of multiple gestations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anatomic survey, as appropriate for gestational age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluation of the uterus, adnexa, and cul-de-sac",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    An embryo is usually visible when the gestational sac diameter is &ge;20 mm, and cardiac motion is usually detected when the embryo is &ge;5 mm (transvaginal examination).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: ACOG Practice Bulletin No. 98. Ultrasonography in pregnancy. Obstet Gynecol 2008; 112:951.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15275=[""].join("\n");
var outline_f14_58_15275=null;
var title_f14_58_15276="TMP-SMX desens 3 day po";
var content_f14_58_15276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F70864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F70864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral TMP-SMX desensitization protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       TMP (mg)",
"      </td>",
"      <td class=\"subtitle1\">",
"       SMX (mg) PO",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose plus formulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Day 1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 AM",
"      </td>",
"      <td>",
"       0.8",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       1 mL 1:10 dilution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       11 AM",
"      </td>",
"      <td>",
"       1.6",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       2 mL 1:10 dilution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1 PM",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       5 mL 1:10 dilution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5 PM",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       10 mL 1:10 dilution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Day 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 AM",
"      </td>",
"      <td>",
"       16",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       2 mL undiluted suspension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3 PM",
"      </td>",
"      <td>",
"       32",
"      </td>",
"      <td>",
"       160",
"      </td>",
"      <td>",
"       4 mL undiluted suspension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 PM",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       200",
"      </td>",
"      <td>",
"       5 mL undiluted suspension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Day 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 AM",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       400",
"      </td>",
"      <td>",
"       One TMP-SMX SS tab",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The solution used on Day 1 may be prepared from the oral suspension (which contains 40 mg of trimethoprim and 200 mg of sulfamethoxazole per 5 mL) by combining 2 mL of suspension and 18 mL of water.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Caumes, E, Guermonprez, G, Lecompte, C, et al. Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997; 133:465. Copyright &copy;1997 American Medical Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15276=[""].join("\n");
var outline_f14_58_15276=null;
var title_f14_58_15277="Likelihood distal symmetric polyneuropathy";
var content_f14_58_15277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated likelihood of distal symmetric polyneuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neuropathic symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diminished or absent ankle reflexes*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diminished distal sensation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distal muscle weakness or atrophy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerve conduction studies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ordinal likelihood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Abnormal",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Normal",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Yes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Normal",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Neuropathic symptoms include numbness, altered sensation, or pain in the feet.",
"    <div class=\"footnotes\">",
"     * Note that ankle reflexes may be diminished in normal people who are &ge;65 years old.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     This phenotype is observed in small-fiber sensory polyneuropathy. Intraepithelial nerve fiber density determination by skin biopsy may be helpful to confirm the diagnosis.",
"     <br/>",
"     &Delta; This phenotype is not a distal symmetric polyneuropathy when nerve conduction studies are normal.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15277=[""].join("\n");
var outline_f14_58_15277=null;
var title_f14_58_15278="Biphasic positive pressure";
var content_f14_58_15278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biphasic intermittent positive airway pressure ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Seymour, CW, Frazer M, Reilly, PM, Fuchs, BD. Airway pressure release and biphasic intermittent positive airway pressure ventilation: are they ready for prime time? J Trauma 2007; 62:1298.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15278=[""].join("\n");
var outline_f14_58_15278=null;
var title_f14_58_15279="Freedom primary endpoint";
var content_f14_58_15279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Survival plot showing freedom from primary endpoint (combined treatment failure, retransplantation, or death) following liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 408px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Includes 1 patient lost to follow-up.",
"     <br>",
"      &bull; Includes 2 patients lost to follow-up.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: O'Grady, JG, et al. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360:1119. Copyright &copy;2002 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_58_15279=[""].join("\n");
var outline_f14_58_15279=null;
